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Given their therapeutic activity, natural products have been used in traditional medicines throughout the
centuries. The growing interest of the scientific community in phytopharmaceuticals, and more recently
in marine products, has resulted in a significant number of research efforts towards understanding their
effect in the treatment of neurodegenerative diseases, such as Alzheimer's (AD), Parkinson (PD) and
Huntington (HD). Several studies have shown that many of the primary and secondary metabolites of
plants, marine organisms and others, have high affinities for various brain receptors and may play a
crucial role in the treatment of diseases affecting the central nervous system (CNS) in mammalians.
Actually, such compounds may act on the brain receptors either by agonism, antagonism, allosteric
modulation or other type of activity aimed at enhancing a certain effect. The current manuscript
comprehensively reviews the state of the art on the interactions between natural compounds and brain
receptors. This information is of foremost importance when it is intended to investigate and develop
cutting-edge drugs, more effective and with alternative mechanisms of action to the conventional drugs
presently used for the treatment of neurodegenerative diseases. Thus, we reviewed the effect of 173
natural products on neurotransmitter receptors, diabetes related receptors, neurotrophic factor related
receptors, immune system related receptors, oxidative stress related receptors, transcription factors
regulating gene expression related receptors and blood-brain barrier receptors.
© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Over the years, neurodegenerative diseases e such as Alz-
heimer's (AD), Parkinson's (PD) and Huntington's (HD) diseases e
have been the main focus of the research in neuroscience, so as to
recognize the cellular changes and pathophysiological mechanisms
involved [1]. This group of diseases is characterized by a gradual
motor and sensorial loss, as well as deficits of perceptual functions,
knowledge and behaviour associated with neuronal death [2]. This
progressive loss of neurons is associated with deposition of pro-
teins in brain leading to changes in its physicochemical properties
[3].
AD is related to amyloid-b (or Ab peptides), which is formed and
deposited in the brain due to the disturbance in the metabolism of
the amyloid precursor protein (APP) e a glycoprotein that un-
dergoes proteolytic cleavage, through the a- or b-secretases, within
the Ab domain. Firstly, Ab monomers aggregate into soluble olig-
omers that then form insoluble oligomers, generating protofibrils
and fibrils. Soluble Ab1-42 oligomers constitute the more toxic form
of the peptide [4]. Moreover, there are aggregates of hyper-
phosphorylated tau-proteins (or t-proteins) that mediate neuro-
pathological processes associated with dementia [5,6] and there is
also a decrease in the acetylcholine (ACh) levels [7]. In the case of
PD, intraneuronal inclusions called Lewy bodies are present in the
substantia nigra. Lewy bodies are composed of abnormal a-synu-
cleinwhich is nitrated, phosphorylated, abnormally conformed and
aggregated, and presents altered solubility. Besides Lewy bodies,
abnormal neurites containing granular material and a-synuclein
filaments (Lewy neurites) are also found in the substantia nigra of
PD patients [8]. PD is also characterized by the loss of dopaminergic
neurons [9]. Finally, in HD, the mutant Huntingtin protein alters
neuronal function e being the striatum neurons more susceptible
to its toxic effects, which explains the motor symptoms of this
pathology [10].
For the cellular communication, it is necessary a set of physical
and chemical stimuli that exert their effects on certain proteins,
such as biological receptors. The latter regulate a certain physio-
logical function in response to certain molecules [11,12]. In the case
of brain receptors, they can be divided into four major types,
depending on whether they are ionic channels activated by ligands
(ionotropic), G protein-gated ion channels (metabotropic), re-
ceptors with enzymatic activity (kinase-linked receptors) or re-
ceptors that regulate gene transcription (nuclear receptors) [13,14].
The process of neurodegeneration is related to changes in brain
and, thus, brain receptors are important targets in the development
of new neuroprotective drugs (Fig. 1). Actually, proteins such as Ab
peptides have the ability to influence the transmission of excitatory
neurotransmitters e for example, ACh and glutamate e withconcomitant deleterious effects on brain processes, such as learning
and memory [15]. Excessive release of calcium ions (Ca2þ) e for
instance, through glutamate receptors e contributes to mitochon-
drial dysfunction, activation of proteases and mechanisms of
apoptosis, as well as to the accumulation of reactive oxygen species
(ROS) and to the release of nitric oxide (NO) [16]. In turn, g-ami-
nobutyric (GABA) inhibition, mediated by the type A receptor
(GABAAR), is a key element that provides the basis for synchronized
neuronal activity [17]. In addition, the loss of dopaminergic neurons
is a key mechanism for the neurodegeneration since they are
involved in functions such as voluntary movement, attention,
memory and learning [18]. Furthermore, cannabinoid receptors are
also involved in the process, either by a decrease in the expression
of cannabinoid type 1 receptors (CB1Rs) ewhich is associated with
an increased release of glutamate, thus contributing to excitotox-
icity mechanisms [19]e or by overexpression of cannabinoid type 2
receptors (CB2Rs) e which are involved in processes of neuro-
inflammation [20,21]. In addition, the activation of receptors of
advanced glycation end-products (RAGE) in neuronal cells pro-
motes synaptic dysfunction and, in microglia cells, induces
inflammation [6,15]. At the genetic level, peroxisome proliferator-
activated receptors (PPARs) play a crucial role in downregulation
of mitochondrial dysfunction, oxidative stress and neuro-
inflammation [22]. Such mechanisms of neuroinflammation
involve cells from the immune system (for example, microglia)
which, in response to a persistent stimulus (for example, by protein
aggregates), activate the production of neurotoxic factors that
amplify the inflammatory states. At the same time, the scavenger
receptors (SCARs) e highly expressed in astrocytes and microglia e
are involved in the capture of several substrates, such as oxidized
proteins, lipids and apoptotic cells [23]. Receptors related to neu-
rotrophic factors (NTF) regulate the growth, differentiation and
survival of the neurons from the central and peripheral nervous
system, and a greater expression of p75 neurotrophin receptors
(p75NTR) and a lesser expression of tropomyosin/tyrosine receptor
kinases (Trk) contributes to the development of neurodegenerative
diseases [24]. Moreover, inhibition of insulin/insulin-like growth
factor (IGF) signalling contributes to the pathogenesis of AD, as it
increases the activity of kinases that catalyses t-protein hyper-
phosphorylation and Ab oligomer accumulation [5]. Finally, in the
blood-brain barrier, receptors such as low-density lipoprotein
receptor-related protein 1 (LRP1) carry several ligands, such as Ab
and Apolipoprotein E (ApoE)-Ab complexes (ApoE-Ab) [25], influ-
encing the supply of cholesterol for neuronal development and
maintenance of plasticity and function of neurons [25e27].
Regarding natural products, it is important to underline the
enormous diversity of classes of compounds, namely flavonoids,
alkaloids, terpenoids and fatty acids, among others, which can bind
Fig. 1. General view of different types of receptors and their abnormalities in neurogenerative diseases. The brain receptors are important targets for the treatment of neurode-
generative diseases. In fact, aggregates Ab, a-synuclein and the mutant protein huntingtin can directly modulate the transmission of excitatory neurotransmitters as acetylcholine
and glutamate, with disastrous consequences to brain processes, as knowledge and memory. Also, the interaction of the aggregates with dopamine receptors takes to loss of
dopaminergic neurons, as well as decrease or up-regulation of GABA receptors, involved in the synchronization of neuronal activity. It is to emphasize that the downregulation of
cannabinoids receptors CB1 and the excessive activation of glutamate receptors leads to excessive release of Ca2þ and, consequently, to activation of proteases and apoptosis
mechanisms, as well as ROS accumulation and NO release leading, thus, to mitochondrial dysfunction. Besides that, the inhibition of signalization through insulin and IGF receptors,
particularly, leads to Tau proteins hyperphosphorylation and the formation of insoluble fibrils toxic for the neurons. The activation of RAGE receptors, which bind the AGEs (protein
aggregates) takes, among other processes, to neuroinflammation, through production of pro-inflammatory cytokines. The presence of immune system receptors, as Toll-like re-
ceptors and NOD-like receptors, leads to the activation of microglia, through production of TNF-a and IL-1b which promote neuronal death. Also, the upregulation of CB2 receptors,
as well as PPARs and scavenger receptors takes to neuroinflammation processes. Blood-brain barrier receptors, as LRP1, make the transport of ApoE and proteins Ab complexes,
influencing the cholesterol supplement to the neurons. Finally, the aggregates lead to a higher expression of p75NTR neurotrophic receptors and a lower expression of Trk, taking to
the activation of intracellular signalization pathway JNK, which culminates in cell death.
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them to remain in a constitutive state (antagonists). Besides, they
may also be partial agonists, i.e. activate partially the receptor but
not at maximum activity. These compounds may also be inverse
agonists, leading the receptor to the inactive form and, thus, pro-
ducing an opposite effect to an agonist drug [12,28]. Finally, they
may also act as allosteric modulators, i.e. through their binding to
the allosteric centre of the receptor and, consequently, change the
receptor structure [28] e thus, affecting the interaction between
the receptor and the primary ligand e or interfere with receptor
expression (Fig. 2a and b). Indeed, studies addressing the effect of
flavonoid supplementation in humans and animal diets have
shown improvements in cognition function possibly by protecting
vulnerable neurons, enhancing existing neuronal function, stimu-
lating neuronal regeneration and counteracting the oxidative stress
[29]. For instance, epidemiological studies have shown the associ-
ation between tea (Cammelia sinensis L.) consumption and the
reduced risk of AD [30]. Moreover, alkaloid-containing extracts
have been used as therapeutic agents for over 3000 years. Their role
in the central nervous system (CNS) is well known, either by the
neuroprotective effect that characterize some of them or by the
additive effect caused by using so-called recreational drugs [31]. It
is also worth to mention the protective role of carotenoids, vitamin
E and omega-3 fatty acids against age-related cognitive impair-
ments [32,33].
This review summarizes the effect of 173 natural compounds on
brain receptors, focusing on their potential role in the treatment of
neurodegenerative diseases. Whenever possible, a discussion on
the receptor-natural product binding mode will be introduced,
based on studies from molecular docking and molecular dynamicsimulations, in order to understand deeply the interactions
involved. The structures of all 173 natural compounds are displayed
in the supplementary data and were drawn according to
Refs. [34e43].
2. Neurotransmitter receptors
2.1. Acetylcholine receptors
Neurotransmitter receptors with affinity to ACh, the ACh re-
ceptors (AChRs), can be classified as nicotinic (nAChR) or musca-
rinic (mAChR) types [15].
2.1.1. Nicotinic acetylcholine receptors (nAChRs)
nAChRs are ionotropic receptors and consist of glycoproteins
present in nicotinic cholinergic synapses. In mammals, they are in
the muscle junction of the peripheral and CNS. As the term sug-
gests, they have affinity for nicotine, one of its agonists, and are
composed by different pentameric combinations with similar a, b,
g, d and ε subunits, which transport Naþ, Kþ and Ca2þ ions through
the plasma membrane [44].
nAChRs appear mostly in the form of heteromers with a com-
bination of at least 2 subunits: an a subunit, which has the agonist
binding site (positive face); and an accessory unit with b, g or ε
subunits (negative face). However, some receptors may be present
in the form of homomers, such as nAChRa7 or nAChRa9, where
each subunit has two binding site faces [7,15].
The most expressed nAChR in the mammalian brain is the
heteromer a4b2 receptor, which presents two different stoichi-
ometries, (a4)3 (b2)2 and (a4)2 (b2)3, the former having low
Fig. 2. a) Models of binding mechanisms between ligands and receptors. b) Amplitude of receptor response to different types of ligands.
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[7,45]. The homomer nAChR a7 is the second most expressed and
has about 20-fold more permeability to Ca2þ than the other nAChRs
[45]. Its activation leads to an increase in intracellular Ca2þ, which
in turn activates cell survival pathways involving the protein
calmodulin, phosphatidylinositol 3-kinase (PI3K), and phosphory-
lated protein kinase B (AkT) with subsequent upregulation of B-cell
lymphoma 2 (Bcl-2), contributing to the synaptic plasticity. In
addition, these receptors are present in astrocytes, activating
several signal transduction mechanisms that culminate in the
modulation of plasticity [45,46].
The subunits of nAChRs vary in length with a highly conserved
transmembrane topology, having an amino (NH2) terminal region
forming a broad hydrophilic domain with about 200 amino acids.
The a (i.e. a1-9) subunits have two cysteine residues, which areessential for ACh binding, whereas the b, g, ε or d subunits are
absent in such residues. In addition, the nAChRs have three hy-
drophobic sequences (M1, M2 and M3) with short hydrophilic
binding loops and another hydrophilic broad domain, which varies
in sequence between the different above said subunits and contains
sites for phosphorylation. Finally, they have a fourth hydrophobic
sequence (M4) and a short carboxyl terminal tail. Each subunit
crosses the membrane four times and the amino (N-terminal or
NH2-terminal) and carboxyl (Ce or COOH-terminal) termini are
oriented towards the synaptic cleft. The cysteine loop is located at
the base of the extracellular domains, which is important for the
communication between the neurotransmitter binding sites and
the ion channel (Fig. 3a) [44,47].
Since the function of a7 and a4b2 nAChRs is critical for knowl-
edge, sensory processing, attention andmemory, the dysfunction of
Fig. 3. ACh receptors. a) Image of 2MAW [47] obtained in Pymol. Structure of the a7
nAChR transmembrane domain, from Homo sapiens, expressed in Escherichia coli. b)
Image of 5CXV [63] obtained by Pymol. Structure of the M1 mAChR, from Homo sa-
piens, expressed in Spodoptera frugiperda.
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AD, Ab peptides may exhibit a high affinity for a7 nAChRs, in the
picomolar (pM) order, leading to the formation of complexes that
influence neurotransmission and synaptic plasticity [48]. On the
other hand, there are studies stating that the modulation of Ab
peptides in these receptors is more complex. In fact, this interaction
may involve an antagonism effect and inhibition of pre-synaptic
nAChRs, causing changes in pre-synaptic Ca2þ levels [15]. Howev-
er, the activation or antagonism of a7 or a4b2 receptors depends on
the microenvironment, as well as the concentration, size and
conformation of the Ab peptides [49]. In the case of PD, nAChRs
promote dopamine release, and a4b2 and a6b2 receptors in the
striatum are responsible for this function [50]. In studies carried out
in brains affected by this pathology e as well as in animal models e
a decrease of a4b2 and a6b2 nAChRs as well as slight decrease of
nAChR a7 was observed [51]. In order to restore the levels of
dopamine/ACh, it is important an activation of the nAChRs re-
ceptors. Finally, in HD, early studies did not reveal any relation
between the levels of nAChRs and post-mortem human HD brains
[52].
Table 1 reports natural products that interact with nAChRs,
either by antagonism or agonism, such as alkaloids e ()-nicotine
(1, Fig. S1), ()-cytisine (2, Fig. S1), (þ)-epibatidine (3, Fig. S1),
anabaseine (4, Fig. S1), (þ)-anatoxin-a (5, Fig. S1), ()-galantamine
(6, Fig. S1), dihydro-b-erythroidine (7, Fig. S1), methyllycaconitine
(8, Fig. S1),()-lobeline (9, Fig. S1), sophoramine (10, Fig. S1), ibo-
gaine (11, Fig. S1), pibocin (14, Fig. S1), crambescidin 359 (15,
Fig. S1) and monanchocidin (16, Fig. S1) e and sphyngolipids e
rhizochalin and its aglycone (12 and 13, Fig. S1) [34,50,53e59].
ACh-binding proteins (AChBP) share 20e24% sequence identity
with the ligand-binding domain of nAChRs and almost all residues
that are conserved within the binding domains of the nAChRs are
also present in AChBP. For these reasons, AChBPs have been used as
model systems to study ligand-nAChR interactions. AChPBs from
freshwater snail Lymnaea stagnalis have also high sensitivity for the
nAChRs ligands ACh, nicotine (1, Fig. S1), cytisine (2, Fig. S1), epi-
batidine (3, Fig. S1) or dihydro-b-erythroidine (7, Fig. S1). Studies of
co-crystal structures of AChBP with these agonists allowed to un-
derstand that the interactions involve a binding site composed by
the loops A, B and C (at the a subunit, referred as (þ) site) and loops
D, E and F (at the b subunit, known as () side). The binding site is
formed by residues of tyrosine, Tyr and tryptophan, Trp from these
loops: from loops A (one residue of Tyr), B (one residue of Trp), C
(two residues of Tyr) and D (one residue of Trp) [55,60]. The ligand-
receptor interaction includes four main binding characteristics: (1)a cation-p interaction within the positively charged amine of the
ligands (agonist or non-peptide antagonist) and the tryptophan
residue at loop B is formed, stabilizing the compound; (2) a
hydrogen bond to the backbone carbonyl of that tryptophan res-
idue is formed, but this interaction is only present for some ago-
nists; (3) also, the ligand forms a hydrogen bond with the hydroxy
group of the tyrosine in loop A; and, (4) the two tyrosine residues at
loop C establish aromatic and/or hydrogen bonds with the ligand.
Residues on the complementary side play a key role in fine-tuning
agonist function and subtype selectivity. In addition, agonists and
small antagonist interact with the main chain by water-mediated
hydrogen bond to a methionine residue at the complementary
subunit, and this binding is important as agonist pharmacophore.
In summary, while agonist interactions with the principal a-sub-
unit are crucial for binding affinity, interactions with key amino
acids present in the complementary b-subunit affect agonist effi-
cacy [55,60].
A plausible molecular mechanism for competitive inhibition of
a4b2 nAChRs by Erythrina alkaloids (such as dihydro-b-eryth-
roidine (7, Fig. S1)) was proposed, in which conserved aromatic
residues within loops A and B of the a4 subunit and a moderately
conserved aspartate (Asp) residue within b2 subunit were pre-
dicted to be involved. The mechanism comprises a hydrogen bond
formed between a4Tyr126 (loop A) and the lactone group of 7,
which contributes to sensitivity to inhibition by this antagonist.
Moreover, 7 forms weak van der Waals type of contact with the
aromatic indole ring of a4Trp182 (loop B) and strong ionic bonds
between its ammonium centre and b2Asp196 (b2 subunit). Indeed,
b2Asp196 is thought to be themajor contributor to the sensitivity of
a4b2 nAChRs to inhibition by 7 [61]. In addition, it was found that
compound 7 stabilizes the loop C in a different way from other
competitive antagonists and it was suggested that this compound
prevent receptor activation by stabilizing the desensitized state
instead of the non-activated state of nAChRs [60].
Finally, structure-activity studies with cytisine (2, Fig. S1) and
some analogues revealed that substitutions at C-3, C-4, C-5, C-12
positions or at the piperidine nitrogen alters the affinity and
selectivity of the ligands for the a4b2 receptor [55].
2.1.2. Muscarinic acetylcholine receptors (mAChRs)
mAChRs belong to the superfamily of G-protein-linked re-
ceptors and consist of 5 subtypes (M1 to M5), composed of an a-
helix transmembrane domain (TM) (TM I to VII), connected by 3
extracellular and 3 intracellular loops (Fig. 3b) [15,62,63]. The re-
ceptors are divided into two distinct classes, according to the signal
transduction mechanism [64,65]. mAChRs M1, M3 and M5 are
couple with Gq/11 proteins. They mobilize inositol trisphosphate
(InsP3) and diacylglycerols (DAG), increasing the intracellular
concentration of Ca2þ, and may also activate other intracellular
messengers, such as nitric oxide (NO) or phospholipase A2,
although these effects are secondary to the elevation of intracel-
lular Ca2þ concentration [64,65]. In turn, M2 and M4 subtypes
affect the signalling through Gi/0 proteins to inhibit adenyl cyclase
(AC) and reduce the intracellular concentration of 30,50-cyclic
adenosine monophosphate (cAMP) [65].
TheM1 receptor is the predominantmAChR in the CNS playing a
crucial role in memory and recognition associated with the hip-
pocampus, as well as in the increase of a-secretase activity, pre-
venting the formation of Ab plaques [15,66]. The use of
acetylcholinesterase inhibitors or muscarinic agonists increases
receptor activation, thus improving cognitive decline and
decreasing Ab plaque formation [65].
The M2 mAChR subtype is predominantly located in the brain-
stem and hypothalamus, being related to the control of ACh release.
Since selective muscarinic M2 antagonism increases cholinergic
Table 1
Natural products interacting with nAChRs and with mAChRs. Structures of the compounds in Fig. S1.
Compound/Natural source Compound class Effect Refs
()-Nicotine (1)
(Nicotiana tabacum L.)
Alkaloid Agonist of several subtypes of nAChRs; Antagonist of
nAChR a9
[50]
()-Cytisine (2)
(Laburnum anagyroides Medik.)
Alkaloid Partial agonist of neuronal nAChRs; Partial agonist of
a4b2 nAChRs
[50,53e55]
(þ)-Epibatidine (3)
(skin of poisonous frog Epipedobates
Anthonyi Noble)
Alkaloid Agonist of several subtypes of nAChRs; Antagonist of
nAChR a9;
Decrease of the a4b2 nAChRs activity;
High selectivity and toxicity, being required the synthesis
of analogues
[50]
Anabaseine (4)
(certain species of ants, Aphaenogaster
sp. Mayr, and marine worms, Nemertines)
Alkaloid Powerful agonist of all types of neuronal nAChRs [50,54]
(þ)-Anatoxin-a (5)
(cyanobacteria Anabaena flos-aquae Brebisson
ex Bornet & Flauhault and Aphanizomenon
flos-aquae Ralfs ex Bornet & Flahault)
Alkaloid Irreversible agonist of nAChRs [56]
()-Galantamine (6)
(Galanthus nivalis L.)
Alkaloid Allosteric potentiation ligand that modulates nAChRs
to increase ACh release
[57]
Dihydro-b-erythroidine (7)
(Erythrina spp.)
Alkaloid Competitive antagonist of a4b2 nAChRs [55,58]
Methyllycaconitine (8)
(Delphinium glaucum S. Watson)
Diterpenoid alkaloid Selective nAChR a7 antagonist [55,59]
()-Lobeline (9)
(Lobelia inflata L.)
Alkaloid Agonist of the nAChRs [57]
Sophoramine (10)
(genus Sophora L., such as S. alopecuroides L.)
Alkaloid Agonist of the nAChRs [57]
Ibogaine (11)
(Tabernanthe iboga Baill)
Alkaloid Blocking of the nAChRs (inhibit nAChRs-mediated
catecholamine release)
[57]
Rhizochalin (12) and aglycone of rhizochalin (13)
(sponge Rhizochalina incrustata Dendy)
Sphyngolipids High potency of binding to nAChRs a7 [34]
Pibocin (14)
(Far-Eastern ascidian Eudistoma sp.)
Alkaloid High potency of binding to nAChRs a7 [34]
Crambescidin 359 (15)
(Australian sponge Monanchora clathrata Carter
and sponge Monanchora unguiculata Dendy)
Alkaloid High potency of binding to nAChRs a7 [34]
Monanchocidin (16)
(sponge Monanchora pulchra Lambe)
Alkaloid High potency of binding to nAChRs a7 [34]
(þ)-Muscarine (17)
(Amanita muscaria (L.:Fr.) Lam., a basidiomycete
mushroom)
Alkaloid Agonist of the M1-M5 mAChRs, producing the same
effects as ACh
[54]
(þ)-Pilocarpine (18)
(Pilocarpus spp.)
Alkaloid Agonist of the M1-M5 mAChRs [67]
Cryptolepine (19)
(Cryptolepis sanguinolenta (Lindl.) Schlt)
Alkaloid Antagonist of the M1, M2 and M3 mAChRs [67]
(þ)-Himbacine (20)
(Galbulimima baccata F. M. Bailey)
Alkaloid Antagonist of the M2 and M4 mAChRs [67,68]
Ebeinone (21)
(Fritillaria imperialis L.)
Alkaloid Antagonist of the M2 mAChRs [67]
Atropine (22) and ()-Scopolamine (23)
(Scopolia tangutica Maxim.)
Alkaloids Very powerful antagonist of the M3 mAChRs [69]
Arecoline (24)
(Areca catechu L.)
Alkaloid Activation of M2 mAChR, but not of the nAChRs [57]
Luteolin (25)
(Compound present in many fruits, vegetables and
medicinal herbs)
Flavonoid Binding activity to M1 mAChRs [70]
Ombuin (26)
(Erythroxylu spp.)
Flavonoid Binding activity to M1 mAChRs [70]
30 ,40 ,50 ,5,6,7-hexamethoxyflavone (27)
(Eremophila debilis (Andrews) Chinnock)
Flavonoid Binding activity to M1 mAChRs [70]
Sitoindosides VII-X (28e31) and withaferin A (32)
(Withania somnifera (L.) Dun.)
Sitoindosides
(acylsterylglucosides);
Withaferin A (steroidal lactone)
Enhancement of M1 mAChRs binding sites [57]
A.R. Silva et al. / European Journal of Medicinal Chemistry 174 (2019) 87e11592overflow by reducing autoreceptor function in both the brain and
the periphery, the development of M2 antagonists for the
improvement of AD symptoms is necessary. M3 and M5 mAChR
subtypes are expressed atmuch lower levels thanM1 andM2 in the
CNS e with M3 being found in the cortex and hippocampus,
whereas M5 have a discrete localization in the substantia nigra.
Finally, M4 mAChR subtype is located in various regions of the
brain, predominantly in the striatum, where they possibly play arole in the control of dopamine release and locomotor activity.
Research studies have revealed that the use of mAChR M4 receptor
antagonists have some usefulness in restoring the dopamine/ACh
balance which is imbalanced in PD [65]. Table 1 tabulates natural
products that interact with mAChRs, namely the alkaloids
(þ)-muscarine (17, Fig. S1), (þ)-pilocarpine (18, Fig. S1), cryptole-
pine (19, Fig. S1), (þ)-himbacine (20, Fig. S1), ebeinone (21, Fig. S1),
atropine (22, Fig. S1), ()-scopolamine (23, Fig. S1) and arecoline
Fig. 4. Glutamate receptors. a) Image of 5FXJ [74] obtained by Pymol. GluN1b-GluN2B
NMDAR structure-Class X, from Rattus norvegicus expressed in Homo sapiens. The red
and blue chains represent the subunits NR1B and NR2B, respectively. b) Image of 5FWY
[87] obtained by Pymol. Structure of the AMPAR GluA2/A3 N-terminal domain heter-
odimer, from Rattus norvegicus expressed in Homo sapiens. The green chains represent
the subunits GluA2, while blue chains show the subunits GluA3. c) Image of 3QLV [99]
obtained by Pymol. Structure of the GluK2/GluK5 (GluR6/KA2) tetramer assembly of
kainate receptors from Rattus norvegicus expressed in Homo sapiens. The blue chains
represent the high affinity subunit GluK5, while the red chains show the low affinity
subunits GluK2. d) Image of 5KZN [106] obtained by Pymol. Structure of M2 mGluRs
from Homo sapiens expressed in Spodoptera frugiperda. (For interpretation of the ref-
erences to color in this figure legend, the reader is referred to the Web version of this
article.)
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Figs. S1) and 3’,40,5’,5,6,7-hexamethoxyflavone (27, Fig. S1); and the
acylsterylglucosides sitoindosides VII, VIII, IX and X (28e31, Fig. S1)
and the steroidal lactone withaferin A (32, Fig. S1) [54,57,67e70].
Molecular modelling studies were carried out in order to un-
derstand how luteolin (25, Fig. S1), ombuin (26, Fig. S1) and
3',4',5',5,6,7-hexamethoxyflavone (27, Fig. S1) interact with M1
mAChR. The authors found that these compounds bind to the
orthosteric site, mainly through non-polar (van der Waals, p-p and
hydrophobic) interactions with several residues such as Tyr106
(TM3), Trp157 (TM4), Trp378 (TM6), Tyr381 (TM6) and Tyr404
(TM7). Structure-activity studies showed that these flavonoids are
able to bind key residues through substituents in ring B (Asp105
(TM3), Tyr 404 (TM7), Tyr408 (TM7) and Tyr381), through the
carbonyl oxygen of the ketonemoiety in ring C (asparagine, Asn382
(TM6) and threonine, Thr192 (TM5)) or C3 at ring C (Trp378) or the
substituents at ring A (Trp157) [70].
Pilocarpine (18, Fig. S1) forms a polar charged interaction with
the conserved Asp105, cationep interactions with the aromatic
residues Tyr106, Trp378, Tyr381, Tyr404 and Tyr408 through their
positively-charged head groups, and hydrophobic interactions with
other residues, including alanine, Ala196 (TM5), and cysteine,
Cys407 (TM7). Moreover, hydrogen bonding between both Thr192
and Asn382 and the carbonyl oxygen atom in pilocarpine tail
groups are formed. Indeed, Thr192 and Asn382 binding is an
important feature for agonist and antagonist binding, respectively,
allowing to distinguish between agonists and antagonists [71].
2.2. Glutamate receptors
Glutamate receptors consist into two classes, namely the iono-
tropic and the metabotropic receptors [15].
2.2.1. Ionotropic receptors
The ionotropic receptors are divided into three classes, accord-
ing to their specific agonists and/or permeability to different ions,
viz. N-Methyl D-aspartate (NMDA), a-Amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) and kainate [72].
2.2.1.1. N-methyl D-aspartate receptors (NMDARs). N-Methyl D-
aspartate receptors (NMDARs) consist of tetramers, with various
subunit configurations in different regions of the brain, being
involved in glutamatergic transmission and synaptic plasticity, as
well as in memory functions and induction of long-term potenti-
ation (LTP) and long-term depression (LTD) of synapses, depending
on the different subunits involved [4,8,15]. In fact, the GluN2B
diheteromers, as mentioned after that, are involved in the induc-
tion of LTD and GluN2A/B triheteromers are related with LTP [73].
This group of receptors are permeable to the Ca2þ and Naþ ions
[69].
Seven subunits were identified in NMDAR, chiefly one GluN1
subunit (or NR1A-H), four GluN2 subunits (GluN2A to D or NR2A to
D) and two GluN3 subunits (GluN3A and B or NR3A and B) (Fig. 4a)
[74]. NMDARs are obligatory heterotetramers mainly composed of
two copies each of the GluN1 and GluN2 subunits, which bind
glycine and L-glutamate, respectively. However, GluN1/GluN3 and
GluN1/GluN2/GluN3 also exist. Glutamate binds to the GluN2
subunit and, for the receptor to be functional, glycine binds
simultaneously as a co-agonist in the GluN1 subunit [8,45,72].
Variations in the proportions of the GluN2 subunits modify the
affinity of the channels to the glutamate ligands as well as the in-
teractions between the GluN1 subunit and the glycine [75].
It should be noted that the GluN2B subunit of NMDAR has been
implicated in the regulation action of Ab oligomers by increasing
the Ca2þ concentration in the dendritic spines, which results in areduction in synaptic density, leading to their dysfunction [15].
Finally, as shown in Table 2 [4,40,52,59e66] amino acids such as
NMDA (33, Fig. S1), cribronic acid (44, Fig. S1) and trans-4-
hydroxypipecolic acid sulfate (45, Fig. S1) function as agonists of
NMDARs, activating the receptors, and consequently, increasing the
Ca2þ intracellular levels, a crucial process for the learning and
production of new memories [4]. On the other hand, NMDAR
antagonism was observed with triterpene saponins (20(S)-proto-
panaxatriol (34, Fig. S1), ginsenoside 20(S)eRh2 (35, Fig. S1) and
ginsenoside 20(S)-Rg3 (36, Fig. S1)), phenylpropanoids (a- and b-
asarone (37 and 38, Fig. S1) and eugenol (39, Fig. S1)), flavonoids
(isoquiritigenin (49, Fig. S1)), curcuminoids (curcumin (50, Fig. S1)),
mono (isoborneol (51, Fig. S1)) and diterpenes (15-methoxy-pinu-
solidic acid (41, Fig. S1)), alkaloids (()-huperzine A (42, Fig. S1),
ibogaine (11, Fig. S1), lophocladine A (46, Fig. S1), rhynchophylline
(52, Fig. S1), isorhynchophylline (53, Fig. S1) and ()-kaitocephalin
(59, Fig. S1)), peptides (conantokins (47e49, Fig. S1) and histo-
granin (57, Fig. S1)), polypeptides and iridoids (8-O-E-p-methox-
ycinnamoylharpagide (55, Fig. S1) and harpagide (56, Fig. S1)),
having pharmacological activity in the CNS, particularly in neuro-
degenerative diseases such as AD, where it is underlined an
excessive activation of NMDARs [77]. Indeed, the referred com-
pounds, acting by NDMARs antagonism, in general way, inhibit the
excitotoxicity mediated by glutamate, thus decreasing the Ca2þ
intracellular levels, promoting an attenuation of oxidative stress
and, consequently, decreasing cells damage [4,78,79].
Table 2
Natural products interacting with ionotropic and metabotropic glutamate receptors. Structures of the compounds in Fig. S1.
Compound/Natural source Compound class Effect Refs
N-methyl D-aspartate (NMDA) (33)
(foot muscle of blood shell Scaphraca broughtonii and tunicate
Ciona intestinalis)
Amino acid Agonist of the NMDARs [78]
Ginsenosides (e.g. 20(S)-Protopanaxatriol (34); Ginsenoside
20(S)eRh2 (35); Ginsenoside 20(S)-Rg3 (36))
(Panax ginseng C. A. Mey)
Triterpene saponins Decrease ionic current mediated by NMDARs;
Antagonists that selectively inhibit NMDAR through the polyamine
binding (ginsenoside 20(s)-Rh2) or glycine binding (Ginsenoside
20(S)-Rg3) sites
[4,68,77]
a- and b-Asarone (37, 38) and Eugenol (39)
(Acorus gramineus Sol. Aiton.)
Phenylpropanoids Neuroprotection against excitotoxicity induced by NMDA or
glutamate; Increase cell survival: inhibition of Ca2þ influx
[79,80]
Isoliquiritigenin (49)
(Glycyrrhiza glabra L.)
Flavonoid Binds to the NMDAR, inhibiting the increase of the Ca2þ influx into
cells induced by glutamate
[4]
15-Methoxy-pinusolidic acid (41)
(Platycladus orientalis (L.) Franco)
Diterpene Binds to the NMDAR; inhibition of excitotoxicity induced by
glutamate, stabilizing Ca2þ homeostasis and attenuating oxidative
stress
[4]
()-Huperzine A (42)
(Huperzia serrata (Thunb.) Trevis.)
Alkaloid Block of toxicity induced by NMDAR, possibly by binding to the
channel pore
[79,80]
Polypeptides (Achyranthes bidentata Blume) Polypeptides Diminution of NMDA-induced intracellular Ca2þ, through
modulation of the NR2A and NR2B receptor subunits
[4,80]
Nobiletin (43)
(Citrus aurantium L.)
Flavonoid Reverses the NMDAR antagonism by activation of ERK signalling;
Increases protein Kinase A (PKA) activity and phosphorylation of
GluA1 (AMPAR), increasing the post-synaptic response to glutamate
[81]
Cribronic acid (44)
(Cribrochalina olembda, a Paluan sponge)
Amino acid Agonist of the NMDARs [78]
trans-4-Hydroxypipecolic acid sulfate (45)
(Micronesian sponges Axynella carteri and Stylotella aurantium,
as well as from the plant Peltophorum africanum Sond.)
Amino acid Agonist of the NMDARs [78]
Lophocladine A (46)
(Lophocladia sp., a red algae)
Alkaloid Antagonist of the NMDARs [78]
Conantokins -G (47), -L (48), -R, -T (49) and -Prl to -Pr3
(Conus geographus, Conus lynceus, Conus radiatus, Conus tulipa
and Conus parius, a genus of fish hunting snails)
Peptides Selective antagonists of the NMDARs [78]
Ibogaine (11)
(Tabernanthe iboga Baill)
Alkaloid Blocking of the NMDARs [57]
Curcumin (50)
(Curcuma longa L.)
Curcuminoid
(diarylheptanoid)
Inhibitory effects against NMDA stimulation, by decreasing of NR1
subunit phosphorylation; Decreases the expression of mGluR5,
inhibiting glutamate release and consequent excitotoxicity
[80,82]
Isoberneol (51)
(Valeriana officinalis L.)
monoterpene Inhibitory effect on NMDARs when present at low concentrations [83]
Rhynchophylline (52) and isorhynchophylline (53)
(Uncaria rhynchophyliia Miq.)
Alkaloids Inhibition of NMDA-induced current [80]
Gastrodin (54)
(Gastrodia elata Blume)
Phenolic glycoside Suppression of glutamate release induced by NMDAR activation [80]
8-O-E-p-methoxycinnamoylharpagide (55) and harpagide (56)
(Scrophularia ningpoensis Hemsl.)
Iridoids 8-O-E-p-Methoxycinnamoylharpagide suppressed NMDA-induced
cell death more specifically than harpagide; Harpagide suppressed
NMDA- and kainate-induced cell death
[80]
Histogranin (57)
(bovine adrenal medulla)
Peptides Antagonist of NMDARs [76]
trans-Resveratrol (58)
(grapes, peanuts, blueberries and dark chocolate)
Stilbene Increases the levels of AMPAR proteins through increasing
intracellular Ca2þ levels and the consequent activation of AMPK
(AMP activated kinase) and through PI3K/Akt signalling pathway;
Inhibition of excitotoxicity associated with post-synaptic KARs
[91]
()-Kaitocephalin (59)
(fungi Eupenicillium shearii Stolk & Scott)
Alkaloid A competitive antagonist of AMPARs, which acts on GluA2 and
inhibits the mechanisms of excitotoxicity; It has higher affinity for
NMDARs than for AMPARs
[92]
Galactose-binding lectin (marine sponge Cinachyrella sp.) Protein Inhibition of desensitization of AMPARs, acting on the GluA4
subunit
[93]
(±)-Willardiine (60)
(Acacia willardiiana Rose)
Alkaloid Agonist of AMPARs; has been used as a scaffold to produce
antagonists, in order to inhibit excitotoxicity associated with
AMPAR and kainate activation (GluK1 subunits)
[94,95]
Kainate or kainic acid (61)
(seaweeds Digenea simplex (Wulfen) C.Agardh, Alsidium
helmithochorton, Caloglossa leprieurii (Montagne) G.Martens
and Palmaria palmata (L.) Weber & Mohr)
Amino acid Partial agonist of AMPARs; Agonist of KARs, binding to the GluK3
subunit with high affinity, but with low strength; Increases the
levels of glutamate
[78,96]
a-Allokainic acid (62)
(seaweed Digenea simplex (Wulfen) C.Agardh)
Amino acid Partial agonist of AMPARs; exhibit higher affinity and potency to
KARs than to AMPARs
[78]
Domoic acid (63)
(red alga Chondria armata (Kützing) Okamura)
Amino acid High-affinity KARs agonist and partial agonist of AMPARs; Indirect
activation of mGluRs through the release of endogenous excitatory
amino acids
[78,97]
Dysiherbaine (64)
(marine sponges Spongionella chondrodes de Laubenfels and
Lendenfeldia chodrodes)
Amino acid Activation of KARs by high affinity binding to the GluK1 and GluK2
subunits but binds to the GluK5 subunit with low affinity;
Activation of mGluR5, although with an extremely weak affinity
[78]
Neodysiherbaine A (65)
(marine sponge Lendenfeldia chodrodes)
Amino acid High-affinity agonist activity on KARs, with a lesser potency for
AMPARs
[78]
Galectin CchG (marine sponge Cinachyrella sp.) Protein Inhibition of desensitization of KARs, acting on the GluK2a subunit [78]
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Table 2 (continued )
Compound/Natural source Compound class Effect Refs
Willardiine (60)
(Acacia willardiiana Rose)
Alkaloid Selective agonist of the KARs that contain the GluK1 subunits [96]
Caffeine (66)
(coffee flowering plants)
Xanthine Acts in post-synaptic sites, blocking the increase of intracellular
Ca2þ as a result of the activation of mGluRs
[101]
A.R. Silva et al. / European Journal of Medicinal Chemistry 174 (2019) 87e115 95In silico analysis of the binding interaction of conantokins
(47e49, Fig. S1) with the NR2B subunit of human NMDAR was
performed and it was found that residues of glutamic acid (Glu236)
and glutamine (Gln110) were mainly involved in hydrogen bonding
of the NR2B subunit with all conantokins, while hydrophobic in-
teractions were established between residues of isoleucine (Ile110),
phenylalanine (Phe114) and proline (Pro177) of NR2B with those
antagonists [84].2.2.1.2. a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid re-
ceptors (AMPARs). The a-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPARs) consist of hetero-
tetramers composed by GluA1 to GluA4 subunits (GluR1 to R4)
expressed throughout the CNS [72,85,86]. In adult hippocampus,
AMPARs are typically composed by GluA1 and GluA2 or, alterna-
tively, by GluA2 and GluA3 subunits (Fig. 4b) [87]. Each subunit
contains four distinct domains, viz.: an N-terminal; a C-terminal; a
membrane domain consisting of 3 a-helix transmembrane domains
(M1, M3 and M4) and a pore channel loop (M2); and a ligand
binding domain, composed of S1 and S2 polypeptide sections
[86,88,89].
Many of the AMPARs found in the CNS contain GluR2 subunits
and are permeable to Naþ and Kþ ions, but not to Ca2þ. Conversely,
receptors that do not have GluR2 subunit are permeable to all the
three ions [72,85,89]. Particularly, the Ca2þ ion-permeable AMPARs
are involved in synaptogenesis and neural circuit formation [89].
When glutamate is released from the pre-synaptic terminal
nerves, post-synaptic NMDARs and AMPARs mediate the influx of
cations, resulting in excitatory impulses (the excitatory post-
synaptic current, EPSC) leading to cell depolarization [85]. Exces-
sive activation of AMPARs result in excessive release of Ca2þ,
leading to mitochondrial dysfunction, activation of proteases and
mechanisms of apoptosis, as well as to ROS accumulation and NO
release [16,90]. Accordingly, a strategy to be used to limit the
progression of AD could be, for instance, the development of an-
tagonists of Ca2þ-permeable AMPARs, at a pre-symptomatic stage
of the disease [4,8,86]. In Table 2 it can be seen that trans-resver-
atrol (58, Fig. S1) increases the levels of AMPAR proteins leading to
the activation of AMP activated kinase (AMPK) and PI3K/atk sig-
nalling pathway, while the alkaloids ()-kaitocephalin (59, Fig. S1)
and willardiine (60, Fig. S1) act as competitive antagonist and
agonist of AMPARs, respectively [78,81,91e97].
()-Kaitocephalin (59, Fig. S1) displays a differential affinity for
the different subtypes of ionotropic glutamate receptor which is
due to different amino acid compositions of the binding site.
()-Kaitocephalin contains two moieties that can mimic glutamate
and bind to GluA2 subunit of AMPARs. One moiety comprises the
C2 nitrogen as the a-amine group of the glutamate and C1 carboxyl
group as the a-carboxylate of glutamate; In the other moiety, these
functions are displayed by the nitrogen on the pyrrolidine ring and
the C18 carboxyl group, respectively. Crystallography studies have
shown that: (1) C1 carboxyl group interacts with the side chain
guanidinium of an arginine residue (Arg485) and the backbone
amide of Thr480; (2) C2 amine interacts with the backbone
carbonyl of Pro478, the side chain carboxyl of Glu705, and the side
chain hydroxy of Thr480; (3) C18 carboxyl interacts with the amide
of Ser 654 and also with the amide and side chain hydroxy ofThr655 through a water molecule; (4) C3 hydroxy forms an
hydrogen bond with the side chain hydroxy of Ser654; (5) C17
carboxyl interacts with the backbone amides of Tyr450 and Gly451;
and (6) the side chain of Tyr450 forms a hydrophobic surface for the
pyrrolidine ring and C2. Compound 59 has higher affinity for
NMDARs than AMPARs because of the amino acid residues present
in the binding pocket. In GluN1 subunit, Glu657 is replaced by
Ile691 and the hydrophobic Ile side chain may provide a hydro-
phobic surface to interact with the dichlorohydroxybenzoyl group
of ()-kaitocephalin. In a similar way, the substitution of Val484 by
Glu522 is also ideal to form H-bonding with the hydroxy of the
dichlorohydroxybenzoyl group. On the other hand, the water-
mediated H-bond established by Thr655 is prevented by the
replacement of Thr655 by Val689 [92].2.2.1.3. Kainate receptors (KARs). Kainate is a mixed agonist that
also activates AMPARs, leading to misinterpretations of the role of
KARs in the brain [85,88,98]. KARs consist of tetrameric combina-
tions of subunits GluK1, GluK2, GluK3 (or Glu5-7), GluK4 and GluK5
(or KA 1e2) (Fig. 4c) [99]. They may form homomers or heteromers
with low affinity (GluK1-GluK3 subunits), whereas the high affinity
GluK4 and GluK5 subunits only participate in association with the
remaining subunits, leading to the formation of functional re-
ceptors [72,98,100].
In brain, KARs play key roles, such as mediating post-synaptic
depolarization and transporting some synaptic current, though
only occurs in some synapses. In addition, they modulate the
release of neurotransmitters such as GABA and glutamate at
different sites. Finally, KARs play a dominant role in the maturation
of neuronal circuits during their development. These roles are
produced in an unconventional environment, since they imply the
activation of a G protein, leading to the assumption that KARs
would be mostly metabotropic rather than ionotropic receptors.
Nevertheless, as revealed by the crystallized structure, KAR has a
molecular structure similar to that of other ionotropic glutamate
receptors [98]. Besides, these receptors have a high permeability to
Naþ and Kþ [72]. As described in Table 2 some natural products
employ their effects on these receptors, either by activation or
blocking [60,73,78,79]. As examples of KARs agonists, we can
mention the amino acids kainic acid (61, Fig. S1), a-allokainic acid
(62, Fig. S1), domoic acid (63, Fig. S1), dysiherbaine (64, Fig. S1) and
neodysiherbaine A (65, Fig. S1), as well as the alkaloid willardiine
(60, Fig. S1).
X-ray crystal structures have shown that the partial agonists
kainate (61, Fig. S1) and domoate (63, Fig. S1) selected the inter-
mediate and open conformation of GluK2 subunit of KAR, while the
full agonist glutamate selected the closed conformation. The full
cleft closure of GluK2 in the case of these two partial agonists is
preventing by Tyr488 residue [102]. In the ligand-binding pocket,
the amino acids Arg523, alanine (Ala518) and Thr690 are predicted
to be responsible for establishing H-bonding with the a-carboxyl
group of the ligands and Thr690 can also establish indirect in-
teractions through water molecules within the binding pocket that
act as surrogate ligands. Moreover, the a-amino group is predicted
to interacts with Pro516 and Glu738 residues [102].
Dysiherbaine (64, Fig. S1) is the strongest KAR agonist. It has five
key binding groups to interact with GluK1 through hydrogen
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the side chain guanidinium group of Arg523, Ser689 and Thr518,
and the C2 a-amino group H-bonds to the side chain carboxylate
group of Glu738, the side chain hydroxyl of Thr518 and Pro516; (2)
in addition, the g-carboxylate group interact via H-bond with the
side chain hydroxyl of Thr690; (3) the C8 aminomethyl group
hydrogen bonds to the side chain OH of Ser741 and the side chain
carboxylate group of Glu738; (4) The C9 hydroxyl establishes an H-
bond with Glu738; and (5) the tetrahydrofuropyran ring hydro-
phobically packs against the side chains of the residues Tyr489,
Glu441 and Pro516 at the D1 face of the binding pocket. The
replacement of the C8 aminomethyl group by an OH group (in the
case of neodysiherbaine A (65, Fig. S1)) greatly reduces the strength
of the interactions [103].
()-Kaitocephalin (59, Fig. S1) is a low affinity KAR antagonist.
Two important points of interaction on GluA2 (AMPAR) are
different in GluK2 (KAR), which are likely to explain the difference
in affinity of ()-kaitocephalin (59, Fig. S1) for KARs in relation to
NMDARs and AMPARs. The position corresponding to Ser654 in
GluA2 is an alanine in GluK2 (Ala660). This would remove the H-
bond with the C-3 hydroxy group of ()-kaitocephalin. Thr480 in
GluA2 is Ala487 in GluK2, which removes the H-bond with the C-2
amine of ()-kaitocephalin. The loss of two hydrogen bonds could
account for the difference in the inhibition of GluK2 relative to
AMPAR [92].
2.2.2. Metabotropic glutamate receptors (mGluRs)
Unlike ionotropic receptors, which are found primarily on the
post-synaptic membrane and mediate rapid excitatory trans-
mission, metabotropic glutamate receptors (mGluRs) are located in
several membrane compartments of neuronal cell and glia in the
brain and were classified according to their structure and physio-
logical function in three groups [72,104]. Group 1mGluRs (mGluR 1
and mGluR 5) are mostly localized in somatodendritic domains of
neurons, especially in presynaptic regions, whereas Group 2
mGluRs (mGluR 2 andmGluR 3) are present in the somatodendritic
compartment and axonal domains. Group 3 mGluRs (mGluRs 4e8),
with the exception of mGluR 6 which is only located in retina, are
present predominantly in the presynaptic active zone of axon ter-
minals [72,104]. These receptors have an extracellular ligand
recognition domain, seven transmembrane regions connected by 3
extracellular and 4 intracellular loops, and a number of conserved
cysteine residues that may be involved in the receptor conforma-
tion through the formation of intra- or intermolecular disulphide
bonds (Fig. 4d) [104e106].
mGluR 1 and mGluR 5 are coupled to phospholipase C via Gq/11
proteins, promoting the Ca2þ output from intracellular reserves.
These receptors are involved in synaptic plasticity, establishing new
neural networks that form new memories and assist learning
through a process called LTP. Glutamatergic synapses plasticity is
extremely sensitive to Ab aggregates, since they inhibit LTP and
induce LTD. Thus, the loss of functional hippocampal synapses
along with the inhibition of LTP and increase of LTD may be related
to the early learning and memory deficits in AD [72,105,107].
Group 1 of mGluRs stimulates Cb1 phospholipase and the for-
mation of 1,2-diacylglycerol (1,2-DAG) and inositol 1,4,5-
triphosphate (InsP3), with the subsequent release of Ca2þ from
the intracellular reserves through the activation of the InsP3 re-
ceptors. 1,2-DAG remains on the plasma membrane and, together
with Ca2þ, leads to the activation of protein kinase C (PKC) which, in
turn, activates several proteins such as phospholipase D, phos-
pholipase A2, mitogen-activated protein kinase proteins (MAPKs),
as well as several ion channels. Furthermore, activation of PKC
through the mGluR5 and mGluR1 receptors also leads to the
stimulation of NMDARs [105].Homer proteins regulate signal transduction, synaptogenesis
and receptor trafficking, besides maintaining and regulating
extracellular glutamate levels in limboecorticostriatal brain re-
gions [108]. The interaction of mGluR1/5 with homer proteins leads
to the activation of several signalling pathways, including the
binding to InsP3 and rianodine receptors, as well as to Shank pro-
teins, which are part of the NMDA receptor complex. Moreover, the
resulting dimers can also activate AKt through a mechanism
involving pyruvate dehydrogenase 1 (PDK1) and PI3K. The stimu-
lation of group 1 mGluR also leads to extracellular signal-regulated
kinase (ErK) activation, which is important for modelling cell
growth, differentiation and survival [105].
Groups 2 and 3 mGluRs negatively regulate adenylyl cyclase via
Gi/0 and are mostly localized presynaptically, where they act as
autoreceptors to inhibit glutamate or GABA release [72,104]. Even
though a scientific consensus has not yet been reached on the role
of group 2 mGluRs in the pathogenesis of AD, abnormal expression
of these receptors in the hippocampus may be at the basis of Ab
production/release deregulation [105].
Modulation of the mGlu5 and mGlu2/3 receptors represents a
key strategy for PD treatment, since the glutamate and dopamine
systems exert opposite effects. Since mGlu5 activation indirectly
enhances NMDA activity and induces LTD, the use of mGlu5 an-
tagonists reduces the excitatory responses mediated by the acti-
vation of mGlu1 and, hence, the release of glutamate. On the other
hand, the use of mGlu1 antagonists showed limited beneficial ef-
fects. Nevertheless, many effects of the activation of these receptors
are changed in animal models with dopamine deficiency, sug-
gesting that mGlu1 and mGlu5 have redundant roles [109]. In
opposite to mGluR type 1, the mGluR types 2 and 3 inhibit the
release of neurotransmitters. Thus, another possible target would
be the inhibition of glutamate release with mGlu2/3 and mGlu7
agonists, since they have anxiolytic properties and increase
cognitive functions [110]. Table 2 shows natural compounds inter-
acting with mGluRs, namely, curcumin (50, Fig. S1), domoic acid
(63, Fig. S1), dysiherbaine (64, Fig. S1) and caffeine (66, Fig. S1)
[78,80,82,97,101].
2.3. g-Aminobutyric acid receptors (GABARs)
GABA released from the presynaptic terminals activates two
types of receptors (GABAR): the ionotropic GABA type A receptors
(GABAARs); and the metabotropic GABA type B receptors
(GABABRs). GABAARs and GABABRs are located pre- and post-
synaptically. GABAAR is a heterooligomer (Fig. 5) [111] formed by
a diversity of 19 subunits with different isoforms of a, b, g, ε, p and r
[112e114]. All subunits contain common elements such as a hy-
drophilic N-terminal domain exposed to the synaptic cleft, 3 highly
conserved transmembrane domains (TM) (M1, M2 and M3), a hy-
drophilic domain of variable size e with sites for phosphorylation,
separating the M3 and M4 segments, located in the cytoplasm e
and a fourth domain connected to M4 e containing the C-terminal.
The M2 segment is aligned with the channel and contains a small
number of amino acids within the sequence responsible for
anionic/cationic permeability. In turn, the M3/M4 linker consists of
the intracellular domain that binds the cytoskeleton [112].
Like nAChRs, GABARs are part of the superfamily of ion channels
with cysteine loops. Thus, the a subunits of these receptors have a
characteristic cysteine-cysteine pair in the N extracellular domain
[112].
In adult hippocampus, the activation of GABAARs, at rest, leads
to an influx of chloride ions (Cl) through the post-synaptic
membrane, resulting in membrane hyperpolarization and a
decrease in membrane resistance. Thus, GABAAR-mediated inhibi-
tion is a key element that provides the basis for synchronized
Fig. 5. Image of 6D6T [111], obtained by Pymol. Structure of human GABAAR a1-b2-g2
subtype. The green chains represent the subunits b2, the blue cyan ones the subunits
a1, while the chain colored by salmon represents the subunit g2. The grey chains
represent the k Fab light chain and the IgG2b Fab heavy chain is colored by orange. (For
interpretation of the references to color in this figure legend, the reader is referred to
the Web version of this article.)
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results in epileptiform activity. On other hand, in the immature
hippocampus, these receptors have a different role consisting of an
excitatory mediation (excitatory postsynaptic potential, EPSP) [17].
Hence, GABAAR exhibit distinct pharmacological and biophysi-
cal properties, including high affinity for their natural GABA ligand,
slow desensitization rates and long-lasting activity in the presence
of agonists, such as muscimol (68, Fig. S1) and valerenic acid (73,
Fig. S1) (Table 3) [53,57,67,115e118], resulting in low amplitude
currents. Additionally, these receptors are located outside the
synaptic cleft in the pre- and post-synaptic regions, playing a
protective role against excitotoxicity [113]. On the other hand, this
effect is counteracted by GABAAR antagonists, namely the terpe-
noids bilobalide (71, Fig. S1) and picrotoxin (72, Fig. S1) (Table 3).
Studies performed on PD mouse models (6-OHDA) revealed a
decrease in a1, a2, b2 and g2 subunits in globus pallidus [119]. In
HD, there is over-regulation of the various subunits of GABAAR, as
well as of GABABR [114]. GABAARs are dynamic and circulate
constantly between intracellular sites and the plasma membrane,
by endocytosis, being susceptible to changes in GABA levels in the
cellular environment [120]. This over-regulation may be caused in
response to the loss of GABAergic neurons in the striatum of globus
pallidus [114].
Muscimol (68, Fig. S1) interactionwith a1b2g2 GABAAR involves
residues in a1 and b2 subunits [121]. The positive charge is tuckedTable 3
Natural products interacting with g-Aminobutyric acid type A receptors (GABAARs). Stru
Compound/Natural source Compound class Effect
(S)-Reticuline (67)
(Eschscholzia californica Cham.)
Alkaloid Positive mo
Muscimol (68)
(Amanita muscaria (L.:Fr.) Lam.)
Alkaloid Agonist of G
Magnolol (69) and honokiol (70)
(Magnolia spp.)
Lignans Positive allo
honokiol ha
Bilobalide (71) and picrotoxin (72)
(Ginkgo biloba L.)
Terpenoids Receptor an
Valerenic acid (73)
(Valeriana officinalis L.)
Terpenoid Direct partia
()-Epigallocatechin-3-gallate (EGCG) (74)
(Camellia sinensis (L.) Kuntze) and Apigenin (75)
(present in many fruits and vegetables)
Flavonoids Increases sy
Positive secin between the two C-loop aromatic residues b2Tyr205 and
b2Phe200. A salt bridge is formed with b2Glu155 and this residue
was identified as a vital residue for GABAAR-ligand binding and
channel gating. The acidic moiety of 3-hydroxy-isoxazole of mus-
cimol interacts with a1Arg66 and hydrogen bonds with b2Thr202
and a1Thr129. Finally, a p-cation interaction with b2Phe200 is
established. Moreover, the authors argued that a water molecule
could mediate further interactions between muscimol and the
backbone of b2Ser156 and b2Tyr157 [121].
Fuchs and co-workers evaluated the effect of analogues of
magnolol (69, Fig. S1) and 40eO-methylhonokiol as positive allo-
steric modulators of GABAARs. A magnolol analog with an ethyl and
a hexyl residue and a 40eO-methylhonokiol analog with a hexyl
residue and amethoxy groupwere themost potent ones. Smaller or
bulky compounds were less potent [118].2.4. Cannabinoid receptors (CBRs)
The cannabinoid type 1 (CB1R) and type 2 (CB2R) receptors are
G-protein coupled receptors that inhibit adenylyl cyclase. It was
initially assumed that CB2Rs were found only in cells of the im-
mune system; however, they have now been identified throughout
the CNSmainly in microglial cells though at lower levels than those
of the CB1Rs [122].
CB1Rs and CB2Rs, as well as the ligands anandamide (N-
arachidonoyl ethanolamine, AEA) and 2-arachidonylglycerol (2-
AG), and the enzymes fatty acid amide hydrolase (FAAH) and
monoacylglycerol lipase (MAGL) are key elements of the endo-
cannabinoid system, being implicated in physiological functions
such as knowledge, motor activity and immune responses [20].
Both the AEA (high affinity, CB1R-selective partial agonist) and
the 2-AG (moderate affinity, CB1/CB2 full agonist) are synthesized
at post-synaptic terminals from lipid membrane precursors. Both
endocannabinoids are not stored in vesicles but are generated on
demand and then liberated to act in a retrograde fashion on pre-
synaptically localized CB1Rs [21,123]. Such synthesis occurs in
response to high intracellular Ca2þ concentrations, by stimulation
of mGLuR1, or by entry of Ca2þ through the voltage-sensitive
channels [21,122,124]. In the cell, AEA is hydrolyzed to arach-
idonic acid and ethanolamine by FAAH, whereas 2-AG is hydrolyzed
by FAAH and MAGL [122].
CB1Rs/CB2Rs (Fig. 6) [125] share 44% homology and are
composed by 7 transmembrane domain (TM) coupled to Gi/0 pro-
teins that perform different pharmacological profiles and expres-
sion patterns e a dichotomy that provides a unique opportunity to
develop and/or take advantage of pharmacological characteristics
[20,126]. Concerning the structure, in the extracellular surface, an
extracellular loop and an N-terminal region preceding the TM1ctures of the compounds in Fig. S1.
Refs
dulation of a3, a5 and a6 isoforms [53]
ABAARs [67]
steric modulation of GABAARs, particularly in the a2 subunit;
s a stronger effect than magnolol
[57,115,118]
tagonists, acting on Cl channels [115]
l agonist [115]
naptic inhibition mediated GABAA (EGCG has a stronger effect);
ondary modulation of the benzodiazepine drug effect
[115e117]
Fig. 6. Image of 5TGZ [125] obtained by Pymol. Structure of the Human CB1R.
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allows access to lipophilic agonists [126].
CB1Rs are one of the most abundant receptors in the CNS, being
implicated in awide range of brain processes, namely in knowledge
and motor coordination. They are located pre-synaptically at the
axon terminals of GABAergic neurons [114] and their activation
regulates the activity of various plasma membrane proteins and
signal transduction pathways. As example, CB1R activation inhibits
Ca2þ channels, reducing synaptic transmission. It should be noted
that, in a mouse microglial cell culture, the activation of the CB1R
inhibited the release of NO e a major component involved in the
neurotoxic effects of the Ab peptides [20].
CB2Rs are primarily expressed in leukocytes and are also pre-
sent in braine playing a key role in inflammatory processes. Unlike
CB1R, they are highly expressed both in the brains of mice treated
with Ab peptides, as well as in human patients. This overexpression
in the microglia cells may be considered an anti-inflammatory
response of the CNS in order to protect the neurons from their
degeneration. Likewise, it is widely accepted that CB2R activation
triggers immunomodulatory effects, resulting in several changes in
the production of anti-inflammatory substances, increasing prolif-
eration and recruitment of immune cells into the affected tissue
[20,21].
In an early phase of AD and HD, there is a decrease in the
expression of CB1R which is associated with an increased release of
glutamate, contributing to mechanisms of excitotoxicity. In inter-
mediate and advanced symptomatic phases of HD, there is a sig-
nificant loss of CB1R e which is compatible with the hyperkinetic
symptoms of this disease e whereas in AD there is overexpression
of CB1R e which is associated with the akinetic profile of the pa-
tients. Finally, the activation of astrocytes and/or microglia in both
diseases (AD and HD) is related to over-regulatory responses of
CB2Rs and their neuroprotective roles [19].
As showed in Table 4 [19,101,106e126] cannabinoids have
antioxidant activity and full and partial receptor agonists e such as
D9-tetrahydrocannabinol (76, Fig. S1), magnolol (69, Fig. S1), tet-
rahydromagnolol (78, Fig. S1) and 3,30-diindolylmethane (79,
Fig. S1), dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (81,
Fig. S1), dodeca-2E,4E-dienoic acid isobutylamide (82, Fig. S1) and
trans-b-caryophyllene (83, Fig. S1) e inhibit motor activity, which
may be useful for HD, whereas antagonists (e.g. cannabidiol (77,
Fig. S1), betulinic acid (92, Fig. S1), chelerythrine (94, Fig. S1),
sanguinarine (95, Fig. S1), curcumin (50, Figs. S1) and 18b-glycyrrhetinic acid (97, Fig. S1)) produce opposing effects e which
is a useful feature for PD [19].
The interaction of alkylamides with the CB2R was explored by
Raduner et al. [146]. A putative binding site for CB2R ligands is
located adjacent to helices III, V, VI, and VII at the near extracellular
side of the 7TM bundles. The hydrophilic centre is framed by polar
residues (Gln276, Tyr190, and Asp189), and a hydrophobic cleft is
surrounded by aromatic residues (Phe197, Phe117, and Trp258).
Several authors suggested the amino acid residues important for
CB2R ligand activity, which comprise the residues Asp130, Arg131,
Tyr132, Cys174, and Cys175, which are important for the confor-
mation of the wild-type CB2R; the residues Ser161 and Ser165,
which are essential for binding of an antagonist (SR144528); and
the residues Tyr190 and Phe197 needed for the binding of agonists
[147e152]. Similar to the putative cavity of the CB2R model, the n-
alkylamides dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide
(81, Fig. S1) and dodeca-2E,4E-dienoic acid isobutylamide (82,
Fig. S1) are also amphipathic molecules with hydrophilic amide and
hydrophobic alkyl groups, and their flexible molecular features
allowed them to be docked well into the predicted binding pocket.
The computer modelling indicated that the amide group of dodeca-
2E,4E,8Z,10Z-tetraenoic acid isobutylamide (81, Fig. S1) is headed
into the hydrophilic pocket, bounded by the residues Asp189 and
Tyr190 of the CB2R. Tyr190 not only exhibits an H-bond interaction
with the amide hydrogen of the alkylamide but also the aromatic
ring of Tyr190 exhibits p-p interactions with the C2eC3 double
bond in the alkylamide [146].
Sabatucci et al. [153] performed an in silico docking study to find
putative allosteric sites for different allosteric modulators of the
receptor, and to define their binding affinities. Cannabidiol (77,
Fig. S1) binds to the orthosteric site and to the allosteric pockets 1
and 3. On the other hand, the agonist D9-tetrahydrocannabinol (76,
Fig. S1) only binds to the orthosteric site. Pocket 1 was identified in
the transmembrane region between TM2 and TM4, and ligand
binding engaged three amino acids: the conserved residue Trp241
(TM4), the hydrophobic residue Phe237 (TM4), and the positive
residue His154 (TM2). Pocket 3 was found in the N-terminal region
of CB1R, partially overlapping on the orthosteric site and comprises
the residue Cys107; however, interactions in this region were not
completely characterized.
2.5. Dopamine receptors (DARs)
Dopamine or 3-hydroxytyramine is a catecholaminergic
neurotransmitter which generally exerts its actions on the neuronal
circuit through a relatively slow modulation of rapid neurotrans-
mission mediated by glutamate and GABA. Dopaminergic in-
nervations are the most abundant in the brain, being involved in
various CNS functions, including the voluntary movement, atten-
tion, memory and learning [18].
The physiological actions of dopamine are mediated by five
distinct but similar dopamine receptors (DARs) that are coupled to
G proteins e whose topology includes seven hydrophobic trans-
membrane domains (Fig. 7) [154]. All members possess TM amino
acid sequence homology and post-translational modifications
(such as glycosylation and phosphorylation), as well as preserved
amino acid residues involved in interaction with G protein and in
binding agonists [155].
The dopamine receptors are grouped into two major groups (1
and 2), according to their ability to modulate the capacity to pro-
duce cAMP and according to their distinctive pharmacological
properties [18,156e158]. Class 1 DARs include D1 and D5 receptors,
which activate the protein family Gas/olf to stimulate cAMP pro-
duction and are localized exclusively in pre-synaptic neurons. On
other hand, D2, D3 and D4 receptors are coupled in class 2, localized
Table 4
Natural products interacting with cannabinoid type 1 (CB1R) and type 2 (CB2R) receptors. Structures of the compounds in Fig. S1.
Compound/Natural source Compound class Effect Refs
D9-tetrahydrocannabinol (76)
(Cannabis sativa L.)
Terpenoid Partial agonist of CB1Rs and CB2Rs; ROS scavengers; direct
increase of the activity of endogenous antioxidant enzymes
through the modulation of the signalling triggered by the
activation of nuclear factor erythroid 2erelated factor 2
(Nrf2) (indirect effect from the receptors)
[19,122,140,141]
Cannabidiol (77)
(Cannabis sativa L.)
Terpenoid High potency antagonist of CB1Rs and CB2Rs; Direct
increase of the activity of endogenous antioxidant enzymes
through the modulation of the signalling triggered by the
activation of Nrf-2 (indirect effect from the receptors)
[19,122,144]
Magnolol (69) and tetrahydromagnolol (78)
(Magnolia officinalis Rehder&Wilson.)
Lignans Activation of the cannabinoid's receptors [142]
3,30-diindolylmethane (79)
(Brassica spp.)
Alkaloid Partial agonist at CB2Rs [143]
(R)-()-Falcarinol (80)
(species from Apiaceae family, such as Daucus carota L.)
Polyacetylene Inverse agonist of CB1Rs [143]
Dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (81)
and Dodeca-2E,4E-dienoic acid isobutylamide (82)
(Echinaceae purpurea (L.) Moench)
N-alkylamides Agonist of CB1Rs and CB2Rs (high affinity to CB2Rs);
Inhibition of AEA transport; sharing similarities with 2-AG;
partial FAAH inhibition; anti-inflammatory proprieties as
TNF-a mRNA expression but inhibition of LPS-stimulated
TNF- a protein expression (indirect effect from the
receptors)
[127,145]
Trans-b-Caryophyllene (83)
(Found in essential oils of plants such asOriganum vulgare L.,
Cinnamomum sp., Piper nigrum L., Rosmarinus officinalis
L.)
Sesquiterpene Selective full agonist of CB2Rs [127,128,143]
Dodeca-2E,4E-dienoic acid isobutylamide (82), tetradeca-
2E,4Edienoic acid isobutylamide (84), tetradeca-
2E,4E,8Z-trienoic acid isobutylamide (85) and 1-
[(2E,4E,8Z)-tetradecatrienoyl] piperidine (86)
(Otanthus maritumus L.)
Fatty acid derivates High binding affinity to CB2Rs [127]
a and b-Amyrin (87,88)
(Protium kleinii Cuatrec. and Protium heptaphlyllum (Aubl.)
Marchand.)
Triterpenoid The 1:1 mixture of both isomers binds to CB1Rs with high
affinity and to CB2Rs with lower affinity
[127,129]
Cyanidin (89) and delphinidin (90)
(colored fruits and vegetables)
Flavonoids Moderate affinity for human CB1Rs [127,130]
Auroglaucin (91)
(fungus Eurotium repens de Bary)
Alkaloid Binding affinity to CB1Rs and CB2Rs [127]
Betulinic acid (92)
(Betula pubescens Ehrh.)
Triterpenoid Antagonist of CB1Rs and agonist of CB2Rs [127,139]
Celastrol (93)
(Tripterygium wilfordii Hook.f. and Celastrus scandens Lime)
Triterpenoid Agonist of CB2Rs [127,131]
Chelerythrine (94)
(Chelidonium majus L.)
Alkaloid Antagonist of CB1Rs [127,132]
Sanguinarine (95)
(poppy seeds, such as Papaver somniferum L.)
Alkaloid Antagonist of CB1Rs [132]
Curcumin (50)
(Curcuma longa L.)
Curcuminoid
(diarylheptanoid)
Antagonist of CB1Rs [127,133]
Euphol (96)
(Euphorbia tirucalli L.)
Triterpene alcohol Agonist of CB1Rs and CB2Rs [127]
18-Glycyrrhetinic acid (97)
(Glycyrrhiza glabra L.)
Triterpenoid saponin Antagonist of CB1Rs [127,134]
Salvinorin A (98)
(Salvia divinorum Epling & Jativa)
Diterpenoid Agonist of CB1Rs [127,135e137]
Malyngamide B (99)
(marine cyanobacteria Lyngbya spp.)
Fatty acid amide Agonist of CB1Rs and CB2Rs [35,127]
Rutin (100)
(Citrus species, such as Citrus sinensis (L.) Osbeck)
Flavonoid Upregulation of CB1Rs expression [127,138]
Serinolamide B (101)
(Lyngbya spp., a marine cyanobacterium)
Fatty acid amide Moderate affinity and higher selectivity for CB2Rs than for
CB1Rs
[35,127]
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0 proteins, inhibiting the adenylyl cyclase [159].
Class 1 receptors increase the current of the L-type Ca2þ chan-
nels and decrease those of N-type and P-type. Furthermore, D1 can
also mobilize intracellular Ca2þ stores by activating the cAMP
pathway without activating the phosphoinositide (PI) hydrolysis
[159].
Since dopamine is involved in a variety of critical functions, it is
easy to relate dopaminergic dysfunctions to neurodegenerative
disorders e the most notorious being PD [18]. The classic treatment
of this disease involves L-DOPA. Despite time and frequencyadjustments of the drug dose, motor fluctuation and involuntary
movements (dyskinesia) tend to appear in long-term patients
[155]. Generally, agonists increase dopamine function e thus
increasing motor activity e whereas antagonists have an opposite
effect [159]. The alkaloids ()-stepholidine (103, Fig. S1),
()-apomorphine (106, Fig. S1), ()-salsolinol (107, Fig. S1), ibo-
gaine (11, Fig. S1) and ephedrine (108, Fig. S1) are among the nat-
ural products acting as DAR agonists (Table 5), whereas
()-epigalhocatechin-3-gallate (74, Fig. S1) acts as DAR antagonist
(Table 5) [57,160e163]. Since dopamine receptors belong to ami-
nergic G-coupled receptors family, the extracellular loops 1 and 3
Fig. 7. Image of 5WIV [154], obtained by Pymol. Structure of the human D4 dopamine
receptor.
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the active site and forming a lid over the bound ligand. In docking
studies performed with the compound ()-stepholidine (103,
Fig. S1), it was confirmed that the positively charged side chain of
Lys167 forms H-bondswith the negatively charged chain of Glu302.
Then, this bond is broken and Lys167 gradually approaches Asp173
of the extracellular loop 2, forming indirect H-bonds. In D1 re-
ceptors, the distances between the key residues in the active sites
fluctuate a little bit and, so the compound acts as agonist. On the
other side, in the ()-stepholidine/D2 complex, hydrophobic in-
teractions between some groups of the receptor and A and D rings
of the ()-stepholidine occur, thus contributing for a perpendicu-
larity between the rings, as contrary to ()-stepholidine/D1 com-
plex, and so contributes for the antagonism to D2 receptors [161].
Also, docking studies performed with apomorphine (106,
Fig. S1) revealed that, like dopamine, it establishes strong hydrogen
bonds with the residues Asp114 (TM3), Ser193 (TM5) and His393
(TM6) of D2 receptor. The H-bond formed with Asp114 is consid-
ered a salt bridge between a charged oxygen atom from Asp114 andTable 5
Natural products interacting with dopamine receptors (DAR). Structures of the compoun
Compound/Natural source Compound class Effect
Docosahexaenoic acid (102)
(Compound extracted from algae and fatty fish)
Fatty acid u-3 Decreased brain
D (2)-like recept
()-Epigallocatechin-3 gallate (74)
(Camellia sinensis L.)
Flavonoid Antagonist of DA
()eStepholidine (103)
(Stephania tetrandra S. Moore)
Alkaloid Agonist of dopam
L-DOPA (104)
(species of bean as Mucuna spp.)
Amino acid Precursor of dop
Ergotamine (105)
(fungus Claviceps purpurea Tulasnae)
Alkaloid Natural precurso
(D2Rs agonists)
()-Apomorphine (106)
(Papaver somniferum L.)
Alkaloid Agonist of D1 an
()-Salsolinol (107)
(Theobroma cacao L.)
Alkaloid Dopaminergic ac
Ibogaine (11)
(Tabernanthe iboga Baill)
Alkaloid Enhancement of
Ephedrine (108)
(Ephedra sinica Stapf)
Alkaloid Stimulating dopathe protonated nitrogen atom of the ligand. Besides that, His393
residue contributes for a p-p stacking interaction, thus pitch in the
activation of the receptors [164].
3. Diabetes related receptors
3.1. Insulin and insulin-like growth factor (IGF) receptors (IR and
IGFR)
The insulin receptor (IR) has two isoforms (A and B) that differ
slightly in affinity for insulin. The B isoform binds the IGFs with at
least 100 times lower affinity than insulin, while the A isoform has
significantly higher affinity than the B isoform for IGF-I and espe-
cially IGF-II. The IGF-I receptor binds IGF-II with a lower affinity
than IGF-I and insulin with a 500-fold lower affinity [165]. The
insulin and the IGF receptors are heterotetramers assembled from a
and b subunits (a2b2). The a-subunit has a cysteine-rich domain
and a carboxy-terminal (aCT) and contains the site or sites for
ligand binding, whereas the b-subunit is composed by three re-
gions, namely, extracellular, transmembrane and cytosolic domain.
The extracellular portion of each ab protomer contains six domains
(L1, CR, L2, FnIII-1, FnIII-2 and FnIII-3) and an insert domain within
FnIII-2. a- and b-subunits are linked by disulfide bonds. The
greatest similarity between both receptors is found in the tyrosine
kinase domain located in the cytosolic region of the b-subunit
where the homology is 84% [166e168].
This group of receptors are present in the CNS, being expressed
in neurons and glia cells [169]. When ligands bind, subsequent
phosphorylation (activation) of the intrinsic receptor tyrosine ki-
nase (RTK) occurs, promoting signal transduction mechanisms
[5,169]. Signalling of insulin and IGF (Fig. 8a) [170] regulates the use
of glucose and adenosine triphosphate (ATP) production in brain
and is associated with inhibition of apoptosis and regulation of
neuronal plasticity as well as with cholinergic functions e which
are necessary for learning, memory and maintenance of myelin
[169].
Insulin resistance is defined as the state inwhich elevated levels
of circulating insulin (hyperinsulinemia) are associated with
hyperglycaemia. As a result, higher levels of ligand are required to
trigger normal actions of insulin which leads to a set of events that
culminate in negative effects on cells [169].
During caloric restriction, an increase in insulin sensitivity oc-
curs and several signal transduction mechanisms are activated e to
potentiate neuroprotective effects. In particular, the binding of in-
sulin and IGF-I molecules to their receptors leads to the activationds in Fig. S1.
Refs
docosahexaenoic acid produced a decreased density of ventral striatal
ors
[163]
Rs [180]
ine receptor D1 and antagonist of receptor D2 [161]
amine which cannot itself cross the blood-brain barrier [57]
r for semi-synthetic drugs as bromocriptine, cabergoline and lisuride
and perfolide (D1, D2 and D3 receptors agonist)
[57]
d D2 receptors [57]
tivity in D2 receptors [57,162]
release of dopamine; poor affinity for dopamine D1Rs and D2Rs [57,160]
mine D2 autoreceptors [272]
Fig. 8. Diabetes related receptors. a) Image of 4XSS [170] obtained by Pymol. IGF1 in
complex with site 1 of a hybrid insulin receptor/Type 1 IGF receptor, from Homo sa-
piens, expressed in Escherichia coli and Cricetulus griseus. b) Image of 3O3U [274] ob-
tained by Pymol. Structure of human RAGE expressed in Escherichia coli.
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transcription factor kB (NF-kB) [171]. In turn, NF-kB increases gene
expression, namely the genes involved in the neuronal response
(cyclooxygenase, COX, and nitric oxide synthase, NOS) [172].
Furthermore, this signalling cascade also results in the inhibition of
the transcriptional activity of Forkhead box O (FoxO), involved in
neurodegenerative diseases [173].
Thus, inhibition of insulin or IGF actions reduces neuronal sur-
vival, and cell death is triggered by apoptosis, neuronal dysfunction
or activation of death-signalling cascades, as well as by activation of
kinases that phosphorylate tau proteins (t proteins) and other
proteins of the cytoskeleton. Besides, it also promotes oxidative
stress that contributes to the neurodegenerative cascade and, ul-
timately, leads to behaviours associated with dementia and
cognitive deficits [174].
In AD, deficits in brain insulin levels and IGF signalling increase
throughout pathology progression, along with the decreased brain
energy production, gene expression, and plasticity [169]. These
abnormalities are associated with low levels of insulin receptor
substrate (IRS) mRNA, t mRNA, IRS-associated PI3K and phospho-
Akt (activated), and with increased GSK-3b activity and APP
mRNA expression [175]. Thus, AD is associated with insulin resis-
tance and deficiency, and is even called type 3 diabetes [175,176]. As
showed in Table 6 a set of natural products, which includes vitamin
E (109, Fig. S1), trans-resveratrol (58, Fig. S1), ()-epigallocatechin-
3-gallate (74, Fig. S1), theaflavin derivatives (110e112, Fig. S1) and
chaetochromin A (113, Fig. S1), may bring beneficial biological ef-
fects towards relieving symptoms [5,173,177e179].
In silico docking analysis suggested that chaetochromin A (113,
Fig. S1) activates IR by binding to the extracellular domain. It bindsTable 6
Natural products that act on insulin receptors and insulin-like growth factor receptors (I
Compound/Natural source Compound class
Vitamin E (109)
(Compound present in vegetable oils, nuts, whole grains
and green leafy vegetables)
Tocopherol
trans-Resveratrol (58)
(grapes, peanuts, blueberries and dark chocolate)
Stilbene
()-Epigallocatechin-3-gallate (EGCG) (74)
(Cammelia sinensis (L.) Kuntze)
Flavonoid
Theaflavin 3-O-gallate (110), theaflavin-30eO-gallate (111)
and theaflavin 3, 30-di-O-gallate (112)
(Camellia sinensis (L.) Kuntze)
Flavonoids
Chaetochromin A (113)
(fungus Chaetomium gracile Udagawa)
Bis(naphtho-g-pyrone)to the hinge region between the cysteine-rich region and L2
domain. The amino acid residues of the receptor involved in the
interaction of chaetochromin A with IR were found to be Glu287,
Cys288, Thr293, Cys306 and Lys310. Conversely, insulin B-helix
engages the residue Phe39 of the b2-strands at the L1 region and
both insulin chains interact with the carboxy-terminal a-chain re-
gion, being His710, Asn711 and Phe714 residues the most critical
ones. Therefore, chaetochromin A does not bind to insulin binding
site [168,179].3.2. Receptors for advanced glycation end-product (RAGE)
The receptor for advanced glycation end-products (RAGE) is a
member of the immunoglobulin superfamily of cell-surface mole-
cules, being unclassified scavenger receptors that act as receptors of
various ligands, namely advanced glycation end-products (AGEs),
S100 calcium-binding protein B (S100B), high mobility group box 1
protein (HMGB-1), and Ab peptides. Regarding their structure
(Fig. 8b) [180], they are constituted by extracellular, trans-
membrane and cytoplasmic domains. Concerning the extracellular
domain, RAGE have a variable domain (V), involved in the recog-
nition of ligands, and two constant domains (C1 and C2)
[6,15,181e184].
RAGE are highly expressed in neurons, microglia, astrocytes and
endothelial cells. Activation of RAGE in neuronal cells promotes
synaptic dysfunction and, in microglia cells, induces inflammation
[6,15]. AGEs result from the nonenzymatic reaction of reducing
sugars (e.g. glucose) with proteins, lipids, and nucleic acids, and
they accumulate during aging process [185]. The production of
AGEs is increased during hyperglycaemia (diabetes mellitus) and
other serious pathological conditions, such as AD. In AD, toxic
products can be formed due to the inhibition of mitochondrial
respiration caused by an abnormal glucose metabolism. Moreover,
an increase in unchelated transition metals such as copper (Cu) and
iron (Fe) bound to Ab plaques causes, not only an acceleration of the
oxidation of glycated proteins and subsequent increase in highly
reactive glycoxidation products, but also promote the aggregation
of Ab peptides. AGEs were also observed to crosslink neurofibrillary
tangles [4,186].
The interaction between RAGE and their ligands leads to a rapid
production of ROS and pro-inflammatory cytokines through mech-
anisms of signal transduction and activation of transcription factors
e the main signalling pathways activated being Janus kinase (JAK)/
signal transducers and activators of transcription (STAT) cascade,
GTPases Ras-Rac-cell division control protein 42 homolog (Ras-Rac-
Cdc42), PI3K/Akt, MAPK, extracellular signal-regulated kinase 1/
2(ErK1/2), stress-activated protein kinase (SAPK)/c-Jun NH2-termi-
nal kinases (JNK) and mitogen-activated protein (MAP) [181].GFRs). Structures of the compounds in Fig. S1.
Effect Refs
Increases insulin signalling and glucose utilization in the brain,
decreasing the oxidative stress and improving energy metabolism
[177]
Activation of Sirtuin 1 (SIRT1) triggering a similar effect to caloric
restriction: increases insulin sensitivity and activation of Forkhead box
O3a (FoxO3a), a key regulator of insulin and IGF-1 signalling
[5]
Mimics the cellular effects of insulin, reducing gluconeogenesis and
gene expression
[5,178]
Mimics the Forkhead box O1a (FoxO1a) [173]
Mimesis of insulin functions to activate the insulin receptor and its
downstream signalling pathways in vitro and in vivo
[179]
Fig. 9. Neurotrophic factor related receptors. a) Image of 1HCF [195], obtained by
Pymol. Structure of TrkB-d5 bound to neurotrophin-4/5, from Homo sapiens, expressed
in Escherichia coli BL21. The purple chains represent the neurotrophic receptor TrkB,
which is complexed with its ligand, NT4. b) Image of 3BUK [196] obtained by Pymol.
Structure of the Neurotrophin-3 and p75NTR symmetrical Complex, from Rattus nor-
vegicus and Homo sapiens, expressed in Spodoptera frugiperda and Escherichia coli. The
yellow chains represent the neurotrophic receptor p75NTR and the blue chains show
the neurotrohic protein NT3. (For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.)
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from the blood to the brain by transcytosis, inducing cerebrovas-
cular dysfunction e which, in turn, induces in neurovascular
inflammation and consequent synaptotoxicity. Furthermore, RAGE
amplifies the effects of Ab peptides in the early stages of the dis-
ease, when the level of Ab is low [4,6,19].
In PD, a robust expression of the receptors in the substantia
nigra and in the frontal cortex are observed. Increased binding of
AGEs to the RAGE induces and worsens oxidative stress and
inflammation e ultimately leading to mitochondrial dysfunction
and cell death of neurons. AGE-albumin, themost abundant form of
AGE in brain, is synthesized in activated microglial cells and highly
expressed in the nervous system of animal models and in humans
with this disease. In dopaminergic neurons, the expression of RAGE
through these ligands leads to apoptosis of these cells via theMAPK
pathway [181].
Finally, an overexpression of RAGE in the neurons from the
striatum was observed using an animal model of HD [181]. Indeed,
possible causes for elevated RAGE levels were discussed and one
hypothesis raised consisted of the mutated huntingtin protein be-
ing released from the intracellular space into the extracellular space
and subsequently binding to RAGE - triggering a toxic cascade of
cytokines and consequently leading to neuronal death [187,188].
However, researchers found out that huntingtin aggregates did not
bind to RAGE and that the toxic mechanisms of this protein did not
account for all neuronal death associated with the disease,
revealing that other mechanisms were also implicated [185]. In
Table 7 are presented examples of natural compounds which act on
RAGE, in order to reduce the negative effects resulting from their
activation [189e193]. This is the case of trans-resveratrol (58,
Fig. S1) and glycyrrhizic acid (123, Fig. S1) which reduce RAGE
expression, thus ameliorating the disease-associated symptoms.4. Neurotrophic factor (NTF) related receptors (NTFRs)
The family of neurotrophic factors (NTFs) which includes nerve
growth factor (NGF), BDNF, neurotrophin (NT)-4/5 (NT-4/5) and
neurotrophin-3 (NT-3) proteins, regulates the growth, differentia-
tion and survival of CNS and peripheral neurons. All proteins are
initially produced by a pro-NTFs precursor, and are subsequently
processed, by proteolytic cleavage, to mature NTFs that are released
to various cell types, including neurons and glia cells. It is note-
worthy that pro-NTFs have different binding properties and
different functions relative to mature NTFs [24,194]. NTFs act
through two distinct receptors: a high-affinity and selective re-
ceptor tyrosine kinase called Trk (Fig. 9a) [195] and a low affinity
receptor called p75 [24,194].
Mature NTFs bind primarily to one of three Trk isoforms e with
NGF preferentially binding to TRkA, BDNF and NT-4/5 to TrkB, andTable 7
Natural products acting on receptors for advanced glycation end-product receptors (RAG
Compound/Natural source Compound class Effect
(þ)-Catechin (114), ()-Epicatechin (115) and
Proanthocyanidin B2 (116)
(Cinnamomum zeylanicum Blume)
Flavonoids Inhibitory
to capture
trans-Resveratrol (58)
(grapes, peanuts, blueberries and dark chocolate)
Stilbene Reduction
Chrysin (117)
(Passiflora caerulea L.)
Flavonoid Inhibition
apoptosis
Ginsenosides Rg1 (118), Rb1 (119), Rh1 (120),
Rb2 (121), and Rc (122)
(Panax ginseng C.A. Mey.)
Triterpene saponins Decreases
Glycyrrhizic acid (123)
(Glycyrrhiza glabra L.)
Triterpene glycoside Downregu
of solubleNT-3 mainly to TrkC but also to TrkA and TrkB. These NTFs have a
central region that binds to the receptor and three b-loops (loops 1,
2 and 4), inducing the formation of Trk dimers and triggering
autophosphorylation into multiple tyrosine residues of the Trk
cytoplasmic domain. When these residues are phosphorylated,
they form binding site nuclei cores for adaptor proteins, such as,
Src, Shc and growth factor receptor-bound protein 2 (Grb2) e
leading to the activation of signal transduction pathways that
culminate in cell survival/differentiation effects [194].
The p75NTR (Fig. 9b) [196] is a transmembrane glycoprotein and
a member of the superfamily of tumour necrosis factor-a (TNF-a)
receptors, having an extracellular domain with four cysteine-rich
domains (CRD), two of which bind to NTF, and a cell death
domain in the intracellular region [196]. The mature pro-NTF and
NTF ligands form homodimers that bind to the p75NTR dimeric
receptor e which regulates multifunctional cellular processes by
modulating Trk signalling and recruitment of adaptor molecules,
viz.: receptor-associated necrosis factor 1e6 (TRAF 1e6); neuro-
trophin (NT) receptor interacting MAGE homolog (NRAGE); neu-
rotrophin (NT) receptor interacting factor (NRIF); and receptor
interacting protein 2 (RIP2). These adaptor molecules are depen-
dent on the ligand and, according to the existing co-receptor,
determine which signalling pathways will be activated. It should
also be noted that elevated levels of NTF and/or low levels of Trk
promote interactions between p75NTR and TRAF 1e6, NRAGE and
NRIF e leading to the activation of the c-Jun NH2-terminal kinases
(JNK) pathway and cell death [194].
In AD, an increase in p75NTR expression in neurons from the CA1
and CA2 areas of the human brain hippocampus and in rat modelsE). Structures of the compounds in Fig. S1.
Refs
effects on AGEs formation, due to their antioxidant properties and ability
reactive carbonyl species intermediates of AGE
[189]
of RAGE expression in the hippocampus, decreasing Ab accumulation [190]
of AGE/RAGE signalling and consequent oxidative stress, attenuating
of cells
[191]
regulation of the RAGE signalling pathway [192]
lation of RAGE expression, decreasing of circulating AGE by upregulation
RAGE which enhance the scavenging and clearance of AGEs.
[193]
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found to bind to the p75NTR receptor and to form immunoprecipi-
tates e which could be directly responsible for the activation of
p75NTR-mediated cell death. The p75NTR binds to mature NTF and
pro-NTF ligands, with similar affinity but different kinetics, and all
these substrates have a variety of biological effects. In particular, the
biological functions of these p75NTR may be related to the fact that
they act as co-receptors of TrkA and mediate several neurobiolog-
ical functions, such as cell survival/death. Therefore, they appear to
be very important in diseases, being highly over-regulated in
neurodegenerative pathologies. In fact, as the disease progresses
with age, a greater expression of p75NTR and a lower expression of
Trk are observed. Activation of p75NTR signalling pathways in-
creases b-secretase expression and accelerates the production of Ab
peptide aggregates, although their aggregation is inhibited through
the extracellular domain [15,24,197].
In HD, changes in the production of BDNF are observed owing to
the mutant huntingtin protein, and since the binding of BDNF to
TrkB is required for the survival of neurons, this leads to brain
striatum degeneration. Moreover, there is a decrease in mRNA
encoding TrkB and an increase in p75NTRmRNA.With respect to PD,
a direct correlation is found between the decrease of BDNF and NGF,
the neurodegeneration of dopaminergic neurons, and the expres-
sion of TrkB and p75NTR [24,194].
As shown in Table 8 one may find naturally occurring com-
pounds exerting their biological effects on these Trk, either by
direct agonism of TrkB receptors (as in the case of 7,8-
dihydroxyflavone (124, Fig. S1) or deoxygedunin (125, Fig. S1)) or
by stimulating the expression of TrkB (promoted by hyperforin
(126, Fig. S1)) [24,53,198e200]. Such bioactivity has been evaluated
through in vitro and in vivo (rats) models e and emphasizes the
importance to undertake further studies to discover new agonists
of TrK receptors and p75NTR antagonists. Particularly, molecular
docking studies performed with 7,8-dihydroxyflavone (124, Fig. S1)
and TrkB receptors revealed the presence of 3 H-bonds at the Ig2
domain of extracellular regions, in addition to interactions of 124
with the cysteine cluster 2 region of TrkB, like BDNF-TrkB interac-
tion, thus contributing to the receptor dimerization, enhanced TrkB
phosphorylation and promotion of downstream cellular signalling.
Molecular analysis showed that 7,8-dihydroxyflavone is involved in
hydrogen bonding with Leu315, Lys312 as well as Pro313; and a p-s
interaction occurs between B ring of the compound and C265 of
Leu315 [201].
5. Immune system related receptors
Although the inflammatory response is not typically a factor in
the initiation of neurodegenerative diseases, there are evidences (in
animal models) that the inflammatory responses involving micro-
glia, resident macrophages in the brain and spinal cordewhich areTable 8
Natural products interacting with receptors associated with neurotrophic factors (NTF).
Compound/Natural source Compound class Effect
7,8-Dihydroxyflavone (124)
(Present in several plants such as
Tridax procumbens L., Godmania aesculifolia
(Kunth) Standl. and Primula sp.)
Flavonoid Direct rec
dimerizat
ErK1/2 sig
Huperzine A (42)
(Huperzia serrata (Thunb.) Trevis.)
Alkaloid Increases
mammalia
of NGF, BD
Deoxygedunin (125)
(Azadirachta indica A. Juss)
Terpenoid Agonist of
Protection
Hyperforin (126)
(Hypericum perforatum L.)
Phloroglucinol derivative Stimulatiothe first line of defence of the innate immune system e contribute
for disease progression. Microglia cells control the cellular envi-
ronment and produce factors that influence neighbour astrocytes
and neurons, such as NTFs and anti-inflammatory factors
[23,202,203].
For an effective immune response, the initial detection of the
pathogen should be amplified from the recruitment of other cells to
the site of infection, which induce antimicrobial activities and
initiate the development of adaptive immunity. To that purpose,
several genes are activated, such as those encoding cytokine
amplifying molecules (e.g. TNF-a, and the Interleukin-1 b (IL-1b)]
and chemokines that act as a concentration gradient in order to
recruit other cells. In addition, genes encoding proteins with anti-
microbial activity e such as iNOS e and enzymes that generate ROS
e such as nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase e are activated. The latter is an example of a system that
results in side effects in cells of the brain parenchyma [23]. In turn,
elevated NO levels induce neurotoxic effects due to peroxynitrite
(ONOO) formation [204].
In AD, Ab peptide aggregates are detected by microglia cells and
astrocytes through various sensors, such as toll-like receptors
(TLRs), inducing the production of ROS, NO, TNF-a, IL-1b, among
other factors that promote neuronal death [23]. In PD, the aggre-
gation of a-synuclein fibrillary proteins activates microglia cells,
enhancing the neurotoxicity of dopamine [205].
Inflammatory responses are usually initiated by pattern recog-
nition receptors (PRRs) that bind to pathogen-associated molecular
patterns (PAMPs) and damage-associated molecular patterns
(DAMPs), which consist in strange signs to the cell [23,206]. One
known class of PRRs is the TLR, which is present in microglia and
bind to pathogenic molecules not found in the host. There are 10
TLRs in humans. TLR1, TLR2, TLR4-TLR6, and TLR10 are located on
the plasma membrane and primarily recognize microbial mem-
brane components. TLR3, TLR7-TLR9 are found in the lumen of
endocytic compartments, the location where uptaken microbial
components are directed, and where TLRs recognize aberrant
(microbial or autoimmune) nucleic acids [207]. Particularly, the
TLR4 binds to lipopolysaccharides (LPS) of Gram-negative bacteria,
and evidences in transgenic mouse models showed that TLR4
polymorphisms are also found on the basis of neurodegenerative
diseases e such as AD e through binding to the Ab peptide ag-
gregates [23,206]. There is evidence that TLR4 alone is not enough
to recognize LPS, requiring the co-receptor myeloid differentiation
protein 2 (MD-2) to sense the lipid A domain of LPS. MD-2 is a small
protein containing 143 amino acid residues that adopt a b cup fold
with two antiparallel b sheets and constructs a hydrophobic pocket.
The engagement of LPS with TLR4eMD-2 complexes leads to the
dimerization of two TLR4eMD-2 complexes and the activated re-
ceptor multimer recruits two major adaptor molecules, myeloid
differentiation factor (MyD88) and TIR domain containing adaptor-Structures of the compounds in Fig. S1.
Refs
eptor agonist of TrK, mimicking neurotrophin binding; Induces the
ion as well as phosphorylation of the TrkB and consequent Akt and
nalling pathways
[24,198]
BDNF/TrkB signalling, dependent of PI3/protein kinase B (AkT)/
n target of Rapamycin (mTOR) pathways; Increase of the production
NF and phosphorylated MAPK.
[53,198]
TrkB, through the mimesis of BDNF's biological activities.
of the neurons from the apoptosis in a TrkB dependent manner.
[198,199]
n of expression of TrkB [198,200]
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Regarding the structure of TLR4s (Fig. 10) [209] they consist of
type 1 transmembrane proteins with an extracellular domain
composed of leucine-rich repeats (typically 19e25) that mediate
ligand recognition and the receptor dimerization, whose domains
sandwiching the ligands and cause the closing of extracellular and
intracellular domains. Besides that, they contain a transmembrane
domain and a toll/interleukin-11 receptor (TIR/IL-11) domain e
essential for the signal transduction mechanism through homo-
typic interaction of the ligands [207,210].
The binding to PRR leads to the activation of signal transduction
mechanisms that result in the activation of transcription factors e
such as NF-kB e and kinases e such as MAPK. To that purpose, the
TLR associate to adaptor proteins referred above, such as MyD88
and TRIF [23].
Another class of PRR, which is also involved in sensitivity to Ab
peptide aggregates is NOD-like receptors (NLRs). While TLRs are
transmembrane, NLRs consist of soluble cytoplasmic receptors that
act as cell damage sensors and their structure reveal a common
domain organization with a central NOD, a N-terminal effector
domain, and C-terminal leucine-rich repeats (LRRs) [211]. In AD, Ab
oligomers and fibrils induce lysosomal degradation and the release
of NACHT, LRR and PYD domains-containing protein 3 (NALP3), also
known as cryopyrin, expressed in microglia, that activates signal
mechanisms, such as the activation of caspases that culminate in
apoptosis and maturation of pro-inflammatory mediators, such as
IL-1b [23,212].
With respect to the natural products that act on the immune
system receptors (Table 9) [16,36,37,57,213e218] studies have
shown that phenolic compounds, such as trans-resveratrol (58,
Fig. S1), curcumin (50, Fig. S1), chlorogenic acid (127, Fig. S1), bai-
calin (128, Fig. S1), naringenin (129, Fig. S1), ()-epigallocatechin-
3-gallate (74, Fig. S1), magnolol (69, Fig. S1) and honokiol (70,
Fig. S1) can be used for the treatment of neuro-inflammation, for
example through the regulation of TLR2 and TLR4 [213]. They also
act against oxidative stress e through direct action against free
radicals, or by activation of regulatory pathways e through mod-
ulation of signal cascades or overexpression of genes [204]. Other
compounds with great importance are TLR4 antagonists, which
includes lipopolysaccharides (130e132, Fig. S1), berberine (136,
Fig. S1), atractylenolide I (137, Fig. S1) and zhankuic acid A (138,
Fig. S1). On the other hand, morphine (142, Fig. S1) act as TLR4
receptor agonist.
Wang et al. [208] explored the binding mechanism of curcumin
(50, Fig. S1) to MD-2 by molecular docking and molecular dynamicFig. 10. Image of 3FXI [209] obtained by Pymol. Structure of the human TLR4. The
yellow chains represent the ligands. In this case, shows the lymphocyte antigen 96.
(For interpretation of the references to color in this figure legend, the reader is referred
to the Web version of this article.)simulations. Curcumin occupies a large part of the LPS binding site
at the large hydrophobic binding pocket of MD-2. This natural
compound can establish multiple H-bonds with the amino acids
Arg90, Glu92 and Tyr102 of MD-2, mainly through oxygen atoms in
hydroxyl and methoxy groups (O3 and O5). Moreover, Peluso et al.
[219] also reported that xanthohumol (135, Fig. S1) have the same
interaction with Tyr102, highlighting that this amino acid is crucial
for MD2-ligand binding.
6. Oxidative stress related receptors
Scavenger receptors (SCARs) are a diverse family of pattern
recognition receptors (PRRs) that are expressed primarily in as-
trocytes and microglia and are involved in the uptake of several
substrates, namely oxidized proteins, lipids and apoptotic cells [16].
The receptor-ligand interaction triggers endocytosis, phagocytosis,
adhesion and signalling processes, often depending on the collab-
oration of non-scavenger receptors such as TLRs [182,220].
These receptors have been classified into six classes, although
there are some unclassified members remaining. They are all
defined by high affinity and specificity for polyanionic ligands
[182]. Class A scavenger receptors (SCARA) comprises the receptors
that are involved in the defence against bacteria l and viral path-
ogens. Particularly, there are high levels of SCARA member 1
(SCARA-1) in the microglial cells around the Ab plates. Another
member is the macrophage receptor with collagenous structure
(MARCO) that forms complexes with N-formyl peptide receptor 2
(FPRL2) by encountering Ab peptides, then occurring intracellular
signalling through ErK 1/2 and subsequent inhibition of cAMP
[182,221]. The SCARA-1 structure consists of an arrangement of
three coiled extracellular regions with cysteine-rich domains con-
nected to the plasma membrane through a long fibrous “stem”
composed of an a-helix coil and a triple collagen helix, which is
likely to be involved in the binding to substrates through the
collagen-like domain [182].
The class B scavenger receptors (SCARB) provide a response
against bacteria and fungi and, in AD, a high level of SCARB-1
expression is associated with increased Ab peptide deposition. In
addition, cluster of differentiation 36 (CD36)/SCARB member 2
(SCARB-2) is also expressed in microglia and consists of a receptor
that is activated by Ab peptide binding, activating the cells to
produce cytokines and chemokines that induce the migration of
other cells. It is also worth noting that CD36 can also form heter-
odimeric complexes with TLR-4 and TLR-6, resulting in the pro-
duction of ROS and in an increase of mRNA of IL-1b, indicative of the
activation of inflammasomes. The SCARB structure (Fig. 11) [222] is
characterized by the presence of the membrane-bound nitrogen
(N) and carbon (C) terminals and an extracellular wide loop
[182,223]. The class C scavenger receptors (SCARC) are involved in
the phagocytosis of Gram-negative and Gram-positive bacteria,
whereas SCARE contain lectin domains. The relation between
SCARC and neurodegenerative diseases is unknown [182]. Class D
scavenger receptors (SCARD) are characterized by the presence of
an extracellular mucin domain. In AD, there is over-regulation of
CD68/SCARD1 in microglial cells [182,224]. Finally, class F scav-
enger receptors (SCARF) are distinguished by multiple extracellular
replicates and class F scavenger receptor member 1 (SCARF-1) is
also involved in the pathogenesis of AD [181,224]. As summarized
in Table 10 there are natural compounds which act essentially by
decreasing the regulation of the scavenger receptors, such as
()-epigallocatechin-3-gallate (74, Fig. S1), secoiridoids, vitamin E
(109, Fig. S1), curcumin (50, Figs. S1), 3,5,6,7,8,30,40-heptamethox-
yflavone (145, Fig. S1) and 3,6,7,8,30,40-hexamethoxyflavone (146,
Fig. S1) [225e233]. Tannic acid (147, Fig. S1) and sennoside B (148,
Fig. S1) are able to reduce SRA mediated antigen transfer, while
Table 9
Natural products that interact with immune system receptors. Structures of the compounds in Fig. S1.
Compound/Natural source Compound class Effect Refs
trans-Resveratrol (58)
(grapes, peanuts, blueberries and dark chocolate)
Stilbene Downregulation of important enzymes and cytokines in
inflammatory signalling pathways; Acts in upstream in the
activation of the cascade by interfering in the
oligomerization of TLR4 after binding to the receptors
[16,213,214]
Curcumin (50)
(Curcuma longa L.)
Curcuminoid
(diarylheptanoid)
Attenuates the homodimerization of TLR4, necessary for
triggering the signalling cascade pathways; Overexpression
of inflammatory mediators that inhibit the TLR4- MAPK/NF-
kB pathway; Blocks the intracellular production of ROS
linked to NADPH oxidase
[36,37,213]
Chlorogenic acid (127)
(Compound present in coffee, tea, and in the leaves and
fruits of several plants, such as apples, pears, carrots,
tomatoes, and sweet potatoes)
Hydroxycinnamic acid Attenuates mRNA levels and protein expression levels of
pro-inflammatory mediators; suppresses of TLR4-mediated
NF-kB signalling pathway; reduces the levels of pro-
inflammatory cytokines, such as TNF-a, IL-6 and IL-1b
[213,217]
Baicalin (128)
(Scutellaria baicalensis Georgi)
Flavonoid Inhibits the TLR2/4 signalling pathway, reducing the
expression of NF-kB, inducible NOS (iNOS) and COX-2
[16,163]
Naringenin (129)
(Citrus fruits, such as Citrus sinensis (L.) Osbeck)
Flavonoid Downregulation of TLR2 and TLR4 protein expression and
TLR2 mRNA levels
[215]
()-Epigallocatechin-3-gallate (EGCG) (74)
(Camellia sinensis L.)
Flavonoid Decreases regulation of the inflammatory response of
macrophages; Inhibits the production of TNF-a, IL-1b, IL-6
induced by LPS; Stimulates the activation of Nrf2,
eliminating or inactivating ROS; Inhibition of TLR4 signal
downstream
[16,37,213]
Magnolol (69) and honokiol (70)
(Magnolia spp.)
Lignans Inhibition of TLR4 expression up-regulated by LPS,
supressing NF-kB activation and proinflammatory cytokine
expression
[57,218]
Lipopolysaccharides and lipid A (130)
(Rhodobacter sphaeroides)
Lipopolysaccharide Antagonists of TLR4, blocking the formation of the TLR4/
myeloid differentiation factor 2 (MD-2) complex
[36]
Lipooligossaccharide (131) from Bartonella quintana Lipopolysaccharide Antagonists of TLR4, blocking the formation of the TLR4/
MD-2 complex
[36]
Lipopolysaccharide (lipid A displayed in structure 132)
(Oscillatoria planktothrix FP1)
Lipopolysaccharide Antagonists of TLR4, blocking the formation of the TLR4/
MD-2 complex
[36]
Sulforaphane (133) and iberin (134)
(Brassica spp.)
Isothiocyanates Antagonists of TLR4, blocking the formation of the TLR4/
MD-2 complex; Sulforaphane also suppress the LPS-
induced expression of inflammatory genes
[36,37]
Xanthohumol (135)
(hops and beer)
Prenylated chalcone Antagonists of TLR4, blocking the formation of the TLR4/
MD-2 complex
[36]
Celastrol (93)
(Tripterygium wilfordii Hook.f. and Celastrus scandens Lime)
Triterpenoid Antagonists of TLR4, blocking the formation of the TLR4/
MD-2 complex
[36]
Berberine (136)
(Berberis spp.)
Alkaloid Antagonists of TLR4 [36]
Atractylenolide I (137)
(Atractylodes lancea (Thunb.) DC)
Sesquiterpene Antagonists of TLR4 [36]
Zhankuic acid A (138)
(Taiwan fungus camphoratus)
Sterols Antagonists of TLR4 [36]
Cinnamaldehyde (139)
(Cinnamomum spp.)
Aldehyde Inhibition of the activation of NF-kB and IRF3 induced by
LPS; Inhibition of TLR4 oligomerization by LPS
[37]
1-Dehydro-10-gingerdione (140) (Zingiber officinale Rosc.) Phenolic compound Potent inhibitor of LPS-MD2 interaction; Supresses MyD88
dependent NF-kB and Ap1 activation and TRIF-dependent
pathway.
[37]
Glycyrrhizic acid (123) and isoliquiritigenin (40)
(Glycyrrhiza plants, such as as G.uralensis Fisch. ex DC.)
Triterpenic saponin
(Glycyrrhizic acid),
flavonoid (isoliquiritigenin)
Inhibition of NF-kB and MAPK activation, mediated by the
oligomerization of TLR4/MD2, resulting in a decreasing of
production of proinflammatory cytokines
[37]
Paclitaxel (141)
(Taxus brevifolia Nutt.)
Diterpene alkaloid Blocking of NF-kB activation and cytokines expression by
binding MD2 antagonist, ameliorating TLR4 dependent
pathologies
[37]
Morphine (142)
(Papaver somniferum L.)
Alkaloid Agonist action on TLR4 receptors [37]
Chitohexose (143)
(helminths surface glycans)
Sugar Actuation on TLR4 signalling, by competition with LPS as an
antagonist
[37]
Oxyresveratrol (144)
(Morus alba L.)
Stilbene Inhibits the activation of NALP3 [216]
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oligomerization. Docking and molecular dynamic simulations of
the binding of tannic acid (147, Fig. S1), sennoside B (148, Fig. S1)
and rhein (149, Fig. S1) to SCARA showed that Arg351, Ile365,
Leu366, Ser390 and Ser425 are critical residues for binding of these
ligands to SCARA. Mostly, Ile365, Ile426 and Ile 431 of one subunit
form a hydrophobic cavity that interact with rhein backbone
together with the Arg351 residue from the other subunit. Moreover,
the side chains of Ser390 and Ser425 act as H-bond donors andLeu366 backbone carbonyl and Glu427 side chain serve as H-bond
acceptors. These are common features for all these three ligands.
Besides these features, for sennoside B, His367 and Trp434 seems to
be involved in aromatic stacking interaction with the backbone of
the molecule, whereas Val350, Ile365 and Ile426 reinforce the hy-
drophobic interaction with sennoside B. Sennoside B also estab-
lishes watermediated interactions with Arg351. In the case of rhein,
similar interactions involve Arg389 and the hydroxyl group of the
ligand [231,232].
Fig. 11. Structure of scavenger receptors. Image of 4TVZ [222] obtained by Pymol.
Structure of human SCARB2 in Neural Condition (pH 7.5).
Fig. 12. Image of 3D5F [234] obtained by Pymol. Structure of the human PPAR-
d complex.
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receptors
Peroxisome proliferator-activated receptors (PPARs) belong to
the superfamily of steroid hormone receptors. They are a group of
nuclear receptor proteins that function as transcription factors
regulating gene expression. They play an important role in cell
differentiation, cell development, and metabolism (lipid peroxi-
dation) and are activated by gene expression regulatory ligands
[4,5]. There are three classes of PPARs that are expressed in the
braine viz. PPAR-a, PPAR-b/d and PPAR-ge the latter two being the
most abundant [5]. Similar to the other nuclear receptors, the three
subtypes have in common N-terminal transactivation domains,
central highly conserved deoxyribonucleic acid (DNA)-binding
domains, and C-terminal ligand-binding domains (LBDs) (Fig. 12)
[234,235].Table 10
Natural products that interact with the scavenger receptors associated with oxidative st
Compound/Natural source Compound class
()-Epigallocatechin-3-gallate (EGCG) (74)
(Camellia sinensis L.)
Flavonoid
Secoiridoids and their glycosides (Gentiana scabra
Bunge)
Secoiridoids
Vitamin E (or a-tocopherol) (109)
(Compound present in vegetable oils, nuts, whole
grains and green leafy vegetables)
Tocopherol
Curcumin (50)
(Curcuma longa L.)
Diarilheptanoid (Curcuminoid)
Nobiletin (43)
(Citrus aurantium L.)
Flavonoid
3,5,6,7,8,30 ,40-Heptamethoxyflavone (145) and 5-
hydroxy-3,6,7,8,30 ,40-hexamethoxyflavone (146)
(Citrus fruits, such as Citrus sinensis L.)
Flavonoids
Tannic acid (147)
(bark of hemlock, chestnut, mangrove, and oak
trees)
Tannin
Sennoside B (148)
(Cassia senna L.)
Anthranoid
Rhein (cassic acid) (149)
(Cassia senna L.)
Anthraquinone
Fucoidan (150)
(brown seaweeds as Fucus vesiculosus L.)
Sulfated polysaccharide
Ginsenoside Rg3 (151)
(Panax ginseng C.A. Mey)
Triterpene saponinMetabolic pathways are regulated at different levels in response
to environmental or hormonal factors. Thus, PPAR-a promotes the
metabolism and catabolism of fatty acids by overregulating the
genes involved in the transport of fatty acids and their oxidation. In
turn, PPAR-b/d is responsible for the regulation of lipid and glucose
metabolism. Finally, PPAR-g is related to glucose metabolism and
regulation of fatty acid storage, insulin sensitivity and cell growth
[236,237].ress. Structures of the compounds in Fig. S1.
Effect Refs
Stimulation of nuclear factor kB (NF-kB) subunit translocation,
leading to decreasing of scavenger receptor A (SCAR-A) expression,
by suppressing the activity of its promoter zone
[225]
Decreases SCAR-A regulation by significantly reducing extracellular
signal-regulated kinase (ErK) activity in macrophages
[226]
Decreases SCAR-A expression in macrophages;
Decreases mRNA expression and protein expression of cluster of
differentiation 36 (CD36) (a type SR-B)
[227]
Decreases SCAR-A protein expression;
No effect on CD36 protein expression
[228]
Specific SCAR-A inhibition, without affecting protein levels or
expression of plasma membrane receptors
[229]
Inhibitory effect of 3,5,6,7,8,30 ,40-heptamethoxyflavone in oxLDL-
mediated scavenger receptor expression, by decreasing of CD36
mRNA expression. 5-Hydroxy-3,6,7,8,30 ,40-hexamethoxyflavone
reduces the oxLDL uptake but have no effect in downregulation of
CD36 mRNA or proteic expression, instead have effect in
downregulation of SCAR-A.
[230]
Reduction of antigen transfer by SCARA receptor [231]
Reduction of antigen transfer by SCARA receptor [231,232]
Partial dissociation or antagonism of SCARA oligomerization [231,232]
Antagonist of SCAR-A [233]
Increase the expression of macrophage SCAR-A [273]
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regulate the activation of transcription factors e such as NF-kB e
and oxidative pathways. Activation of PPAR-a prevents the syn-
thesis and release of cytokines or the induction of inflammatory
mediators such as COX-2 or adhesion proteins. In turn, the activa-
tion of PPAR-g also reduces NOS and COX-2 expression and pro-
inflammatory cytokines. Besides, PPAR-a and PPAR-g can inhibit
the activation of macrophages and glia cells that contribute to in-
flammatory processes and consequently to neuronal death
[237,238].
In AD, the development of PPAR-a agonists is associated with a
slower cognitive decline, whereas PPAR-g agonists are involved in
the inhibition of Ab-induced inflammation as well as in the release
of Ab peptide [237,238]. In PD, PPAR-g agonists attenuate the
activation of glia cells and prevent the loss of dopaminergic cells in
substance nigra, by induction of intracellular nuclear transcription
factor kBa (IkBa), blockade of NF-kB activation and NO production.
Table 11 enumerates natural compounds that activate or increase
the expression of PPAR- g or PPAR-a. It is worth tomention the class
of flavonoids, which includes icariin (159, Fig. S1), luteolin (25,
Fig. S1), quercetin (160, Fig. S1), kaempferol (161, Fig. S1),Table 11
Natural products that interact with peroxisome proliferator-activated receptors (PPAR). S
Compound/Natural source Compound class Effect
trans-Resveratrol (58)
(grapes, peanuts, blueberries and dark chocolate)
Stilbene Increas
40eOH
(±)-Linalool (152)
(Found in essential oils of over 200 species belonging to
Lamiaceae, Lauraceae family, and Rutaceae families)
Terpene Direct l
oxidati
saturat
Sargaquinoic acid (153) and sargahydroquinoic acid
(154)
(Seaweed Sargassum yezoense (Yamada) Yoshida &
T.Konno)
Carotenoids Dual ag
Osthol (155)
(Cnidium monnieri (L.) Cusson ex Juss., and Angelica
pubescens Maxim.)
Coumarin Activat
induces
Hesperetin (156), naringenin (129) and its glycosides
(157, 158)
(Compounds of Citrus species, such as C. sinensis (L.)
Osbeck.)
Flavonoids All com
manne
Icariin (159)
(Epimedium brevicornum Maxim.)
Flavonoid Over-re
Chelerythrine (94)
(Chelidonium majus,L.)
Alkaloid Potent
phosph
Luteolin (25)
(Compound present in various types of plants, as fruits,
vegetables and medicinal herbs)
Flavonoid Weak p
reporte
Quercetin (160)
(Compound of fruits and vegetables)
Flavonoid Binds t
as parti
Kaempferol (161)
(Compound found in fruits and vegetables)
Flavonoid Binds t
as parti
()-Catechin (162)
(Camellia sinensis (L.) Kuntze)
Flavonoid Binds t
express
20-Hydroxychalcone (163)
(Cinnamomum spp.)
Flavonoid Binds t
as parti
Biochanin A (164)
(Trifolium pratense L.)
Flavonoid Binds t
as parti
Genistein (165)
(Glycine max (L.) Merr.)
Flavonoid Binds t
as parti
6-Hydroxydaidzein (166)
(Glycine max (L.) Merr.)
Flavonoid Binds t
express
60-Hydroxy-O-desmethylangolensin (167)
(Trifolium pratense L.)
Flavonoid Binds t
as parti
Magnolol (69) and honokiol (70)
(Magnolia officinalis Rehder & Wilson)
Neolignan Binds t
as agon
Amorphastilbol (168)
(Robinia pseudoacacia var. umbraculifera)
Stilbene Dual ag
Amorfrutins 1, 2 and B (169,170,171)
(Amorpha fruticosa L.)
Amorfrutins Binds t
as parti
Falcarindiol (172)
(Notopterygium incisum C.T.Ting ex H.T.Chan)
Polyacetylene Binds t
as parti()-catechin (162, Fig. S1), 20-hydroxychalcone (163, Fig. S1), bio-
chanin A (164, Fig. S1), genistein (165, Fig. S1), 6-hydroxydaidzein
(166, Fig. S1), among others, as well as the stilbenes trans-resver-
atrol (58, Fig. S1) and amorphastilbol (168, Fig. S1), the mono-
terpene (±)-linalool (152, Fig. S1), the carotenoids sargaquinoic acid
(153, Fig. S1) and sargahydroquinoic acid (154, Fig. S1), the
coumarin osthol (155, Fig. S1) and the alkaloid chelerythrine (94,
Fig. S1) [16,235,239e253]. Concerning the interaction of PPAR-g to
the ligands, it is important to underline the fact that LBD of the
receptor is a large Y-shaped cavity composed by an entrance
domain, constituted by amino acids as Ala292, Met329, Leu330 and
Leu333; and two pockets, arm I, substantially polar (presence of
amino acids as Cys285, Ser289, His323, His449 and Tyr473) and
arm II, mainly hydrophobic, thus allowing flexibility for the ligand
binding [244,247]. Also, the LBD is constituted by 13 a-helices and a
small four-stranded b-sheet, emphasising that H12 belongs to the
ligand-dependent activation domain (activation function-2, AF-2)
which is essential for ligand binding and PPAR function. H12 and
the loop between H20 and H3 are the most mobile parts of LBD
[247]. According to the literature, PPAR-g partial agonists bind only
to b sub-pocket, while full agonists always occupy both AF-2 and b-tructures of the compounds in Fig. S1.
Refs
es levels of PPAR-g; Direct activation of PPAR-a through the
group of the compound
[16,235]
igand of PPAR-a, reducing cellular lipid accumulation, inducing
on of fatty acids and significantly reducing the concentrations of
ed fatty acids
[235]
onists of PPAR-a and PPAR-g with a slight effect on PPAR-d [235]
ion of PPAR-a through an AMPK-dependent pathway that
receptor phosphorylation
[235]
pounds induce the expression of PPAR-g in a dose-dependent
r; Naringenin activates the PPAR-a
[235]
gulation of PPAR-a and PPAR-g; Inhibition of NF-kB expression [235]
binding to PPAR-a, by blocking the CDK-5-mediated
orylation of the receptor.
[246]
artial agonist/antagonist of PPAR-g; activates PPARg-dependent
r gene expression as partial agonist;
[247,248]
o PPAR-g; activates PPARg-dependent reporter gene expression
al agonist
[247,249]
o PPAR-g; activates PPARg-dependent reporter gene expression
al agonist
[247,250]
o purified PPAR-g; activates PPARg-dependent reporter gene
ion as full agonist
[247,251]
o PPAR-y; activates PPARg-dependent reporter gene expression
al agonist
[247,252,253]
o PPAR-g; activates PPARg-dependent reporter gene expression
al agonist
[239,247]
o PPAR-g; activates PPARg-dependent reporter gene expression
al agonist; Activation of PPAR-a
[240,247]
o purified PPAR-g; activates PPARg-dependent reporter gene
ion as full agonist
[241,247]
o PPAR-y; activates PPARg-dependent reporter gene expression
al agonist
[242,247]
o PPAR-y; activates PPARg-dependent reporter gene expression
ist
[243,244,247]
onist of PPAR-a and PPAR-g [245,247]
o PPAR-y; activates PPARg-dependent reporter gene expression
al agonist
[247]
o PPAR-y; activates PPARg-dependent reporter gene expression
al agonist
[244,247]
Fig. 13. Image of 3MOC [255] obtained by Pymol. Structure of human LDL receptor.
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like amorfrutins 1, 2 and B (169,170,171, Fig. S1) which are partial
agonists present high affinity due to the interaction of the carboxyl
group to Ser342 of the b-sheet via hydrogen bonds, as well as
binding to Arg288 of H3. Particularly, amorfrutin B (171, Fig. S1)
shows significantly higher affinity due to its long geranyl side chain,
which forms additional hydrophobic interactions to Arg288 of H3
[247]. Besides that, the compound luteolin (25, Fig. S1) interacts by
two hydrogen bonds with Lys265 and His266 at the U loop that
links H20and H3 and makes hydrophobic contacts with various
amino acids, as Phe264, Gly284, Phe287, Cys285, Arg288, Leu330,
Ser342, Ile341, Met364, and Val339 [247,248]. Also, a water mole-
cule seems to be involved on the binding of luteolin to the LBD
[247]. In this case, luteolin (25, Fig. S1) occupies the region of PPAR-
g delimited by the H3 and the b-sheet, not contacting H12 [248].
Concerning magnolol (69, Fig. S1), two molecules of magnolol
cooperatively occupy the PPAR-g, since one molecule occupies AF2
through the hydroxyl group that makes a hydrogen bond with
Ser289 in H3 and water-mediated bonds with Tyr473. The other
molecule binds to the b-sheet, by a hydrogen bond between hy-
droxyl group of the magnolol and Ser342. Also, it exists a water-
mediated hydrogen bond in the b-sheet to magnolol to further
stabilize the ligand binding [243,247]. Additionally, the compound
chelerythrine (94) establishes interactions with PPAR-g mainly
through a water molecule between the group methoxy of the
compound and the carbonyl oxygen of the amide from Ile326.
There is also a water-mediated bond within the nitrogen or
carbonyl oxygen of an amide from Leu353, Phe360 andMet364 and
the heterocyclic group of the chelerythrine [246].
8. Blood-brain barrier receptors
8.1. Apolipoprotein E (ApoE) or low-density lipoproteins (LDL)
One of the genetic variations of AD is related to an allelic variant
of apolipoprotein E (ApoE, a 34 kDa protein) ewhich acts in part as
a lipid transporter, existing three isoforms of ApoE, namely: ApoE2,
ApoE3 and ApoE4 [23]. In brain, ApoE is mainly produced by
microglia and astrocyte cells and plays important roles in binding
to members of the low-density lipoprotein (LDL) receptor (LDLR)
family e such as the classical LDLR and the pro-low-density lipo-
protein receptor-related protein 1 (LRP1) e thereby making the
chemical binding, the internalization and catabolism of lipoprotein
neuronal development and for maintaining the plasticity and
function of neurons [23,26].
At the cellular level, cholesterol secreted by glia cells through
ApoE is incorporated into membrane compartments of neurons by
endocytosis via LRP1. LRP1 is a 600 kDa multifunctional scavenger,
transporter, signalling and endocytic receptor, highly expressed in
brain e essentially in the cell bodies of neurons and dendritic cells,
thus participating in cell signalling, as the activation of Ras/MAPK
and AKT pathways [254]. LRP1 (Fig. 13) [255] consists of a non-
covalent heterodimer composed by a heavy chain containing four
putative binding domains as well as by a light chain containing a
transmembrane domain and a cytoplasmic tail [26,256]. There are
two forms of LRP1: one associated with the cell surface (LRP1) and
another truncated soluble (sLRP1), normally found in plasma,
resulting from the action of the enzyme b-secretase that cleaves the
extracellular domain of LRP1 [25].
In the CNS, this type of receptor is correlatedwith neuronal stem
cell proliferation and synaptic strength [254]. Besides that, LRP1
transports several ligands, such as Ab peptides and ApoE-Ab com-
plexes, through the blood-brain barrier [25]. It is important to note
that the expression of the latter is associated with high cholesterol
levels and defects in Ab release e leading to the accumulation of itsaggregates in brains of patients with AD [26]. In addition, lipo-
protein receptors may contribute to AD through a decrease in LRP1
expression which, in turn, leads to changes in Ab transport and,
consequently, to the accumulation of such peptides in brain [25], as
confirmed in AD mouse models subjected to LRP1 deletion,
showing reduced plasma Ab, elevated soluble brain Ab, and deficits
in spatial memory, thus emphasising the LRP1 function in systemic
Ab elimination [257]. On the other hand, the receptors may be
related to the processing of APP [26]. Intensive research efforts are
being conducted toward the development of novel therapies that
act on LRP1, including the resource to natural products (Table 12)
[230,258e264]. For instance, eicosapentaenoic acid (173, Fig. S1),
docosahexaenoic acid (102, Fig. S1), 5-hydroxy-3,6,7,8,30,40-hex-
amethoxyflavone (146, Fig. S1) and curcumin (50, Fig. S1) affects
LDLR expression and activity, particularly by activation of the re-
ceptors, thus increasing LDL levels and ApoE in brain, promoting
the delivering of the cholesterol essential for the neuronal activity
and decreasing the formation of amyloid protein levels in AD.
However, several studies revealed that this beneficial effect was
only observed in individuals who contains the ApoE4 allele
[229,256,258,259,262,263].
9. Toxicity of natural compounds
It is worth underlining that there are natural compounds that
also have toxic effects in humans and more studies are needed to
establish the safe dose window. For example, despite the antioxi-
dant effects of D9-THC (76, Fig. S1), it consists of a partial agonist of
the CB1R and CB2R e which has damaging effects on memory e
whose effect can be attenuated by another plant-based compound,
the cannabidiol (77, Fig. S1). It has been demonstrated in animal
studies that D9-THC induces dose-dependent toxicity and struc-
tural changes in brain regions rich in CB1Rs (hippocampus, amyg-
dala, cerebellum, prefrontal cortex, and striatum). In humans,
studies are not so consistent but changes in the hippocampus/
parahippocampal complex and in the amygdala have often been
reported [265]. Likewise, compounds such as epibatidine (3,
Fig. S1), even being agonists of nAChR, are extremely toxic e thus,
may only be at the base of the synthesis of analogues. Indeed,
epibatidine causes hypertension, respiratory paralysis and seizures.
Death occurs at doses not much higher than those required for
antinociception [266].
Atropine (22, Fig. S1) and ()-scopolamine (23, Fig. S1) act
Table 12
Natural products that interact with ApoE or LDL receptors. Structures of the compounds in Fig. S1.
Compound/Natural source Compound class Effect Refs
Eicosapentaenoic acid (EPA) (173) and Docosahexaenoic
acid (DHA) (102)
(Active compounds of fish oil)
u-3 fatty acids LDLR downregulation. In individuals containing the ApoE4 allele,
supplementation of elevated levels of DHA is associated with increased
low-density lipoprotein (LDL) levels
[258,259]
Quercetin (160)
(Compound present in several fruits and vegetables)
Flavonoid Increase of ApoE levels and decrease amyloid-b (Ab) protein levels [260]
Vitamin E (a-tocopherol) (109)
(Compound present in vegetable oils, nuts, whole grains
and green leafy vegetables)
Tocopherol Increases circulation of lipoprotein particles and LDL; Beneficial effects
observed only in individuals not containing the ApoE4 allele
[261,262]
Curcumin (50)
(Curcuma longa L.)
Curcuminoid Increases LDLRmRNA expression resulting in an increase in plasma LDL-
cholesterol uptake and consequently increases ApoE in brain
[263,264]
5-hydroxy-3,6,7,8,30 ,40-hexamethoxyflavone (146)
(citrus fruits, such as Citrus sinensis (L.) Osbeck)
Flavonoid Upregulation of LDLR activity [230]
A.R. Silva et al. / European Journal of Medicinal Chemistry 174 (2019) 87e115 109pharmacologically via blocking mAChRs. The blockage of these
receptors causes symptoms like tachycardia, dilated pupils,
decreased gastrointestinal motility, dry hot skin and dry mouth due
to a decreased sweat and saliva production. Apart from these pe-
ripheral effects, atropine also affects CNS and causes agitation,
disorientation and hallucinations [267]. Cytisine (2, Fig. S1) binds
with a high affinity to nAChRs. Like nicotine (1, Fig. S1), cytisine acts
as a blocking agent on CNS via an over stimulation of these re-
ceptors. Thus, the symptoms of a poisoning are like a nicotine
overdose, causing delirium and convulsions. Death can occur
through a respiratory paralysis or failure of the circulatory system
[267].
A large percentage of the users consume ibogaine (11, Fig. S1) for
treatment of a substance-related disorder and, more than half,
specifically for opioid withdrawal. The most prevalent side-effects
of ibogaine are ataxia, tremors, muscle spasms, toniceclonic sei-
zures and severe nausea. A rise in blood pressure and a decline in
pulse rate have been recorded 1e5 h after ibogaine administration.
It was also reported one case in which permanent cognitive deficits
and loss of vision remained for weeks after hospitalization. Death
due to cardiotoxicity can occur [268].
Domoic acid (63, Fig. S1) is structurally similar to another
known toxic, kainic acid, which activate iGluRs with the partici-
pation and co-activation of AMPARs (partial agonists)/KAs (ago-
nists) and NDMARs receptor subtypes. In the brain, dendrites seem
to be preferential early target sites for its excitotoxicity. The high
concentration of iGluRs in the hippocampus and other brain re-
gions provides targets for the selective cellular and structural
excitotoxicity damage associated with domoic acid, leading to
seizure and cognitive dysfunction. Also, it is observed an acute
injury of astrocytes characterized by vacuolation and necrosis. Be-
sides that, it was reported induction of the retinal injury caused by
domoic acid, as well as spinal cord lesions characterized by focal
hemorrhage, neuronal swelling and vacuolization in animals 1e2 h
after domoic acid injection. Cardiovascular clinical manifestations
were also observed due to the stimulation of NDMARs in the car-
diomyocyte, leading to a Ca2þ, ROS and caspase-3 mediated
pathway [269].
Another case is salvinorin A, which is a selective, high efficacy
agonist at kappa-opioid receptors (KOPRs) [270]. For that reason,
KOPR agonism in the temporal and parietal cortices could underlie
the visual and auditory modifications (temporal cortex) and the
altered experience of the body (parietal cortex), thus salvinorin A
being a powerful hallucinogenic [270,271].10. Conclusions
In recent years, several studies have demonstrated the impor-
tance of brain receptors in the mechanisms of neurodegenerativediseases. As illustrated in this revision manuscript, there is a huge
variety of natural compounds that interact with brain receptors,
exerting beneficial or toxic effects.
Flavonoids, such as epigalhocatechin-3-O-gallate, have a mul-
tiplicity of effects, namely: increasing GABAA-mediated synaptic
inhibition; mimicking the cellular effects of insulin; anti-
inflammatory responses, such as the case of the inhibition of
TNF-a and IL-1b production; MAPK and NF-kB inhibition;
decreasing NO production; and decreasing SCARA expression,
among many other examples. It is important to underline that they
may also exert effects at the level of DAR through increasing the
levels of dopamine e as is an example the effect exerted by bai-
calein. Furthermore, the key role of resveratrol (stilbene) in
numerous receptors such as RAGE, glutamate, insulin, IGFR and
PPAR should also be highlighted.
On the other hand, terpenoids such as D9-tetrahydrocannabinol
found in Cannabis sativa L. act as ROS scavengers or increase the
activity of antioxidant enzymes. Regarding the alkaloids, this group
includes compounds such as nicotine, anabaseine and muscarine
that can act as agonists for nAChR and increase the beneficial
properties resulting from their activation. Additionally, they may
act by blocking excitotoxicity mediated by excessive activation of
glutamate receptors, by activation of GABAARs, by increased acti-
vation of dopamine receptors and by increase BDNF/TrkB signal-
ling. With respect to tocopherols, such as vitamin E, they mediate
processes such as increasing insulin signalling, decreasing oxidative
stress, and decreasing regulation of SCARA as well as CD36 re-
ceptors. In addition, docosahexaenoic acid, an u-3 fatty acid, re-
duces apoptosis of dopaminergic cells and leads to down-
regulation of LRP1.
Nevertheless, it is worth underlining that there are natural
compounds that also have toxic effects.
In short, the constant search for new natural compounds, their
isolation, purification and characterization aim at attenuating
symptoms associatedwith different neurodegenerative diseases. To
that, comprehensive studies on brain receptors and associated
biochemical mechanisms are required, so that their effects can be
elucidated and novel applications can be unfolded.
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